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SUMMARY 
Chronic obstructive pulmonary disease (COPD) is characterized by chronic and abnormal lung 
inflammation leading to progressive and irreversible airflow obstruction. According to the latest World 
Health Organization (WHO) estimates, 64 million people currently have moderate to severe COPD, and 
WHO predicts that COPD will become the third leading cause of death worldwide by 2030. 
Validation of a new murine model of COPD 
Since COPD is a multifactorial disease, it is difficult to reproduce a valid animal model that is able to 
express all the phenotypical features clinically observed in patients. The main experimental protocols 
used so far require genetic approaches or the exposure of animals to noxious stimuli, such as tobacco 
smoke and irritant agents. In the literature to date no protocol has considered chronic treatment with 
multiple risk factors. The aim of this study was to develop a model of COPD, exposing animals to 
environmental conditions similar to those of patients with COPD in order to reproduce a chronic 
inflammatory state, emphysema and bronchial remodelling. The validation of this model was useful for 
therapy studies. 
Mice were exposed for 1, 3 or 6 weeks to the main COPD risk factors: cigarette smoke; 
lipopolysaccharide to mimic bacterial exacerbations of the disease and particulate matter (PM-10) from 
urban pollution.  
The first week of exposure is able to induce an increase in inflammatory cytokines, which progressively 
reduce in the following weeks. Real time PCR has shown, from the third
 
week, an increase in gene 
expression of TGF and αSMA (key factors in the remodelling pathway) and proteolytic enzymes, with a 
peak in the sixth week of exposure, confirmed by immunochemistry and Western blot. Histological 
analysis showed a progressive thickening of the bronchial wall, destruction of lung tissue, enlargement of 
air spaces (emphysema) and the formation of lymphoid follicles, in particular in the sixth week of 
combined treatment.  
Thus, the use of this new experimental protocol is able to trigger inflammatory processes which, in the 
later stages of exposure, induce destruction of the lung parenchyma and airway remodelling (bronchial 
wall thickening, goblet cell hyperplasia and B-cell follicles), which are irreversible after treatment 
cessation. This demonstrates that the pathogenesis observed in mice reflects the natural history of COPD.  
Effect of anti-inflammatory and bronchodilator therapy administered in the early stage of 
COPD 
The therapeutic goal of COPD treatment, in addition to clinical improvement, is the modification of the 
natural history of the disease, reducing mortality. Nevertheless, all available therapies are essentially 
symptomatic and contribute to improving the quality of life, without counteracting the progressive decline 
4 
 
of the lung function. In contrast to current GOLD guidelines, which provide the use of inhaled 
corticosteroids in advanced stages of COPD (when tissue remodelling has already been occurred), the aim 
of this study was to test the hypothesis that a combination of bronchodilators and anti-inflammatory 
treatment is able to influence the progression of COPD only in early stages of pathogenesis, when tissue 
damage is less relevant and bronchial structural changes are still reversible.  
Mice with COPD-like phenotype were treated with a combination of antinflammatory (fluticasone) and 
bronchodilators (salmeterol and tiotropium) drugs, at different times:  
 mice early treated (treatment started at the first week of exposure to risk factors, for 4 weeks);  
 mice late treated (treatment started at the sixth week of exposure to risk factors, for 4 weeks).  
Pharmacological treatment significantly decreases level of cytokines in a group early treated compared to 
untreated. No significant effects were observed in groups treated later, since levels of cytokines resulted 
similar between group untreated and those treated. Early therapy was able to attenuate the activation of 
remodelling processes (bronchial wall thickening, goblet cell hyperplasia, formation of  B cell follicles). 
Moreover, therapy in the first stage of the disease was able to reduce the degree of lung tissue destruction 
(emphysema). No significant effects on bronchial remodelling were observed in groups treated later. 
These data confirmed that a bronchodilator and antinflammatory therapy began too late is not able to 
counteract tissue changes, despite effective action on gene and tissue expression of remodelling factors. 
Instead, an early pharmacological treatment reduced the peak of inflammation contributing to attenuate 
bronchial alterations that are still reversible. Thus, the addition of an anti-inflammatory drug to 
bronchodilator therapy in the early stages could be a useful new therapeutic strategy to reduce the extent 
of bronchial obstruction and to effectively counteract the progression of the disease.  
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1.CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
1.1 DEFINITION 
Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality and 
represents a significant economic burden throughout the world. The Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) defined COPD as a preventable and treatable disease with some 
significant extrapulmonary effects that may contribute to the severity in individual patients. Its 
pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually both progressive and associated with an abnormal inflammatory response of the 
lung to noxious particles or gases.
1
  
It is possible to prevent the disease increasing smoking cessation, treating patients with primary asthma 
or detecting early the disease in order to reduce exposure to risk factors. Extrapulmonary effects are 
frequently observed in patients with COPD, related to impairment of respiratory function: these are 
cardiovascular diseases, osteopenia, chronic infections, reduced fat mass, depression and anxiety.
1
 
Airways obstruction in COPD is linked to several lung mechanisms, such as parenchymal destruction 
and bronchial wall thickening that together contribute to the narrowing of bronchial lume. COPD is not 
fully reversible since the limitation does not revert, even after the use of bronchodilators and anti-
inflammatory drugs. 
1.2 EPIDEMIOLOGY AND RISK FACTORS 
Globally, COPD is now the fourth leading cause of death, representing a worldwide social problem since 
as it is expected to become the third leading cause of death in the next 20 years. Currently, more than 
219 million people have the disease in the world (more than 15 million in the United States).
2,3
 
Traditionally, COPD is a disease that predominantly affects males; however, NHANES studies in United 
States showed that the prevalence of moderate COPD in woman increased during the last 20 years, in 
contrast to the prevalence in men that decreased during the same period.
4,5
 A similar trend has been 
observed in other developed countries, whereas in developing ones the prevalence of COPD is still 
higher in men compared to woman.
6,7
 
COPD is a multifactorial disease induced by exposure to environmental factors (tobacco smoke, air 
pollution, work exposure, respiratory infections) and host factors (age, gender, genetic predisposition) 
acting singly or synergistically among themselves.
8
 Tobacco smoke is the main risk factor for the 
disease, but in industrialized and developing countries additional risk factors are important and 
preventable causes of COPD. 
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1.2.1 ENVIROMENTAL RISK FACTORS 
Tobacco smoke Several epidemiologic studies have shown that cigarette smoking is the most important 
risk factor for COPD. Smokers have lung function abnormalities and a progressive decline in forced 
expiratory volume in the first second (FEV1); moreover, mortality of COPD in smokers compared to 
non-smokers is at least 7 times higher in light smokers (1-14 cigarettes/day), 10-fold increased in 
moderate smokers (15-24 cigarettes/day) and 21-fold in heavy smokers (≥ 25 cigarettes/day).9 Reducing 
the number of cigarettes smoked daily has a significant positive effect on health; indeed, an encouraging 
study demonstrated that who stopped smoking at an age between 35 and 44 years showed a survival 
curve that was similar to that of non-smokers.
10
 Po Delta study from Northern Italy confirms the 
relationship of smoking and COPD: a higher prevalence of chronic cough and mucus hyperproduction 
was found in smokers compared to non-smokers in both sexes.
11
  
A population-based study by Hagstad
12
 showed that exposure to passive smoke is a risk factor among 
never-smokers to develop COPD. The relationship becomes stronger with increasing exposure. In 
multiple environmental tobacco smoke exposure settings the risk of developing COPD is even 
comparable to moderate smoking. Active and passive maternal smoking has a negative effects during 
human pregnancy: maternal smoking is associated with placental damage in all trimester of pregnancy, 
indeed tobacco toxins dysregulate trophoblastic and fetal cells biological functions; effects are reduction 
of fetal growth and weight, fat mass and most anthropometric parameters.
13
 
Each puff of a cigarette contains than 2000 xenobiotic compounds, 10
14
 free radicals, toxins including 
cyanide, sulphides, cadmium, carcinogenic hydrocarbons, nicotine and nitric oxide that injure lung tissue 
by different mechanisms, such as increased release of proteolytic enzymes by immune cells, reduced 
anti-proteases defences, lipid peroxidation of membrane, cleavage of proteins and increase in epithelial 
permeability. Tobacco smoke is known to cause increased sequestration of neutrophils in the pulmonary 
vasculature and airspaces in humans, with alterations in the oxidant/antioxidant balance.
14
 Oxidative 
stress is responsible for many of cigarette smoking effects, since oxidants, such as H202, have been 
shown to inhibit apoptosis and induce necrosis. Moreover, cigarette smoke condensate decreases 
epithelial-cell adherence and increases detachment and lysis in a human type II alveolar epithelial-cell 
line.
15
  
Air pollution  While active cigarette smoking is the most important preventable risk factor globally, 
outdoor and indoor air pollutants can cause or exacerbate COPD. In developed countries there is a clear 
evidence that exposure to high levels of outdoor air pollutants is associated with increased mortality and 
morbidity due to COPD and related cardiorespiratory diseases. The degree of exposure to outdoor air 
pollutants however is variable over time primarily due to changes in pollutant emissions and weather 
conditions. Studies in the last 20 years continue to show increased risk associated mainly with particulate 
matters, even at much lower levels. Populations in low-income countries are largely exposed to indoor 
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air pollutants from the combustion of biomass fuels, such as coal, straw, animal dung, crop residues and 
wood which are used to heat and cook in poorly ventilated homes; this condition contributes 
significantly to the burden of COPD-related diseases, particularly in non-smoking women.
16
 
A recent multinational study performed in Latin America (ESCALA) has shown that levels of particulate 
matter are significantly associated with increased mortality from respiratory and cardiovascular causes, 
in particular COPD.
17
 Another recent cohort study demonstrated that long-term exposure to elevated 
traffic-related fine particulate air pollution (black carbon, particulate matter with aerodynamic diameter 
<2,5μm, nitrogen dioxide and nitric oxide) and wood smoke was related to an increased risk of COPD 
hospitalization (+15%) and mortality (+7%).
18
 
Several studies have shown that air pollutants, such as particulate matter, ozone (O3) and NO2 can 
produce deleterious effects on lung tissue: increase in bronchial reactivity
19
, airway oxidative stress
20
, 
pulmonary and systemic inflammation
21
, amplification of viral infections
22
 and reduction in airway 
ciliary activity.
23
 
                                        
Occupational risk Exposure to dusts, vapours, chemicals and fumes in the workplace is associated with 
an increased risk of developing COPD, in particular in countries of low and middle income, where 
occupational exposures to noxious compounds could be greater than high-income countries because of 
less severe laws. Exposure to high levels of organic particles such as bacterial/fungal toxins (farming 
activities), cotton dust (textile industry), mineral dusts or heavy metals (industrial work) is associated 
with an increased risk of obstructive lung disease.
24
 The risk is lesser than that of smoking and 
interactions between smoking and occupational exposure to various agents is relevant. A study 
performed in Northern Italy demonstrated the relationship between work exposure and COPD: among 
exposed workers there was an increase in symptoms of bronchitis and a decrease in lung function 
compared to not exposed.
25,26
 
Respiratory infections Infections have an important role in development and progression of COPD, as 
they could predispose to bronchiectasis or changes in airways responsiveness. Epidemiological studies 
have demonstrated the association between childhood respiratory infections and the presence of 
symptoms and reduced lung function in adulthood.
27
 In the general population study of Po Delta, a 
higher prevalence of respiratory symptoms and diagnosed COPD was noted in subjects with previous 
childhood respiratory infections compared to those without, particularly in smokers.
28
 
Furthermore, bacterial and viral infections commonly induce COPD exacerbations that are linked to 
worsening the quality of life
29
 and rapid decline in lung function with more frequent and longer lasting 
hospital admissions.
30
 The typical viruses known to cause exacerbations are rhinoviruses, which cause 
most common colds, followed by respiratory syncytial virus (RSV), influenza, coronaviruses and 
parainfluenza viruses (PIVs). Severe acute exacerbations are associated with a high risk of death, with 
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about 10-30% of the subjects dying during hospital admission and about 40-60% dying during the year 
following admission.
31,32
 
 
1.2.2 ENDOGENOUS RISK FACTORS 
Genetic factors It is clear that there is a high variation in susceptibility to COPD between individuals 
due to genetic factors which have a key role in the development of the disease, regulating the lung 
responses to environmental exposures. The best known genetic factor linked to COPD is a deficiency of 
the serine protease 1-antitrypsin, which affects 1-3% of patients with COPD: although 1-antitrypsin is 
mainly produced in the liver, its main function is to protect the lung against proteolytic damage from 
neutrophil elastase; therefore, lower concentrations of this enzyme increase the risk of alveolar 
destruction and emphysema, particularly in combination with smoking or other exposures.
33
 The 1- 
antitrypsin deficit is due to a hereditary defect of two alleles of the protein situated in the gene locus of 
the segment of chromosome 14q32.1. The homozygote phenotype PiZZ has been associated with a 
severe form of pulmonary emphysema. Not every homozygote individual develops the disease, as 
tobacco smoking is generally necessary. Moreover smoking also seems to significantly increase the risk 
of disease in the heterozygote forms.
34
 
Numerous other genes have been studied and implicated in COPD susceptibility, based on various 
pathogenic pathways, such as inflammation (interleukin-4, -6, -13, TNF, TGFβ), protease/antiprotease 
balance (MMP-9, TIMP2, SERPINA3) and oxidative stress (glutathione transferase, superoxide 
dismutase).
35
 
Ageing COPD prevalence, morbidity and mortality increase with age. Lung function reaches its peak 
level in young adults and starts to decline in the third and fourth decades of life.
36
 The link between 
aging and the pathogenesis of COPD is strongly supported by numerous studies
37-38
: senescence is a 
complex outcome of endogenous and environmental factors (ex. oxidative stress) and therefore the role 
of cigarette smoke, noxious gas and air pollutants is a key factor linking aging lung to COPD. 
Gender Several studies suggested a gender difference in susceptibility to harmful effects of smoking in 
the lung: women may be biologically more susceptible to the adverse effects of cigarettes than men, due 
to sex differences in smoke metabolism.
39
 The airways in women are anatomically smaller and each 
cigarette may represent a proportionally greater exposure.
40
 Dimensional, immunological and hormonal 
determinants are other biological possibilities for a gender difference.
41
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1.3 PATHOGENESIS OF COPD 
The hallmark of COPD is the abnormal chronic inflammation in the lung in response to inhalation of 
noxious agents, mainly cigarette smoke. Host factors including genetic susceptibility, epigenetic changes 
and oxidative stress contribute by amplifying inflammation induced by cigarette smoke.
42
 The epithelial 
cells of the airways and alveoli are a major source of inflammatory mediators and proteases. Triggered 
by smoking, they produce several factors (TNF, TGF, IL1, IL8, GM-CSF) which cause activation of 
fibroblast and small airways fibrosis. The epithelial cells protect the lung through the production of 
mucus which traps bacteria and compounds (defensins, cationic proteins) which have antimicrobial 
properties. Cigarette smoke or other toxic and irritants agents induce the release of pro-inflammatory 
cytokines and chemokines also by alveolar macrophages, eliciting the expression of adhesion molecules 
on endothelial cells and the recruitment of neutrophils and inflammatory monocytes to the lungs. 
Activated dendritic cells induce adaptive immune responses encompassing CD4+ T cells, CD8+ 
cytotoxicity and B cells responses, which lead to the development of lymphoid follicles. This condition 
causes lung destruction, through the release of oxygen radicals and proteolytic enzymes (elastase, 
metalloproteases) with consequent bronchial remodelling.
43
 
1.3.1 AIRWAYS INFLAMMATION 
Innate immune response Airways have innate defence mechanisms encompassing the epithelial barrier, 
mucociliary clearance, humoral factors and cells (macrophages, dendritic cells, monocytes, neutrophils, 
natural killer cells and mast cells). Innate immunity is a rapid, aspecific response to infections and tissue 
injuries that stimulate the development of specific adaptive immune responses. Acute exposure to 
noxious factors leads to the release of pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs) molecules. The recognition of PAMPs and DAMPs by several 
families of pattern recognition receptors (PRRs) expressed in alveolar macrophages, dendritic and 
epithelial cells is crucial in mediation of inflammatory responses to infections and tissue damage. The 
PRRs include transmembrane Toll-like receptor (TLRs), cytosolic NOD-like receptors (NLRs) and RIG-
I-like receptors (RLRs). Xenobiotic compounds and free radicals contained in cigarette smoke injure 
lung epithelial cells and extracellular matrix to a degree that is directly proportionate to their 
concentrations. Products derived from injury (hyaluronate, byglican) are ligands for TLR4 and TLR2 
leading to the activation of nuclear factor kB (NF-kB)
44,45
 that induce epithelial cells to produce 
inflammatory cytokines. These mediators are able to activate alveolar macrophages
46,47
 which secrete 
further cytokines (IL8, IL1β, TNF, GM-CSF, MCP-1, ICAM-1) eliciting the expression of adhesion 
molecules on endothelial cells and the recruitment of neutrophils and inflammatory monocytes to the 
lungs. Numbers of neutrophils and macrophages are increased in the lungs of smokers and patients with 
COPD. Activated neutrophils and macrophages cause lung destruction through the release of oxygen 
10 
 
radicals and proteolytic enzymes, such as neutrophil elastase and matrix metalloproteinases (MMPs). 
Elastase, cathepsin-G and proteinase-3, secreted by neutrophils, cause over-stimulation of submucosal 
mucous glands and goblet cells. This chain of events induces dendritic cells to mature and migrate to 
local lymphatic organs; stimulation by TLRs leads to the expression of CD80-CD86 and cytokines, 
creating a propitious environment for T-cell antigen presentation and proliferation into effector CD4+ 
type 1 helper (Th1) T cells and cytolytic CD8+ T cells. Interleukin-6, secreted by dendritic cells, favours 
the production of effector T cells by overcoming the signals from regulatory T (Treg) cells. Upon 
activation, effector T cells express tissue-specific chemokine receptors. CD8+ T cells and natural killers 
contribute to lung damage through the release of other proteases (granzyme B and perforin).  
In this step, if innate inflammation is minimized or controlled, inflammation processes will not progress 
to adaptive immunity and the disease may be arrested.
48
 
 
Fig. 1 Innate immune response following smoke exposure.  
Source: Cosio et al. N Engl J Med 2009
48
 
Adaptive immune response Adaptive immune inflammation is characterized by the presence of CD4+ 
type 1 helper (Th1) T cells, cytolytic CD8+ T cells and IgG-producing B cells.  
CD8+ cytotoxic T cells are predominant in large airways, small airways and lung parenchyma.
49,50
 The 
number of CD8+ T cells in the lung correlates with the degree of airflow obstruction and emphysema, 
suggesting their role in tissue injury. In the lung of smokers with COPD, epithelial and endothelial cells 
undergo apoptosis and this process is correlates with the number of CD8+ T cells and proteases (perforin 
and granzymes) secreted in the lung. This condition contributes to lung destruction in COPD.
48
 
CD4+ T cells are also found in large numbers in the airways and parenchyma of smokers with COPD. 
The effector functions of the CD4+ T cell are mainly mediated by Th1 cytokines, which promote 
transendothelial migration of inflammatory cells to site of injury.
48
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B cells are increased in large airways of patients with COPD; moreover, they organized into lymphoid 
follicles around small airways and in lung parenchyma of patients, especially in the severe stages
51,52
. 
Lymphoid follicles are anatomically and functionally well organised and consisting of memory and 
naïve B cells, T cells, dendritic cells, essential for T-cell and B cell priming and clonal expansion.
53
 
These lymphoid follicles are responsible for antigen retention, immunoglobulin class switching and 
affinity maturation; B cells are oligoclonal in nature, suggesting antigen-specific induction of the B cell 
follicles: antigens involved could derive from microorganisms, cigarette-smoke, breakdown products of 
extracellular matrix and autoantigens.
53
 Therefore, the pathogenic role of the follicular B-cell response is 
controversial: it might be beneficial if protective against microbial colonisation and infections in the 
airways; or it could be destructive if directed against lung tissue antigens, suggesting an autoimmune 
component in COPD. 
The recruitment and activation of inflammatory cells, macrophages, neutrophils, eosinophils, CD4+ and 
CD8+ T cells, and B cells progress as COPD worsens. 
 
Fig.2 Adaptative immune response in COPD.  
Source: Cosio et al. N Engl J Med 2009
48 
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1.3.2 EMPHYSEMA 
Emphysema is defined as an abnormal permanent enlargement of peripheral airspaces of the lung, 
including respiratory bronchioles, alveolar ducts and alveoli, accompanied by destruction of alveolar 
walls. Human emphysema was originally described by Laennec
54,55
, who noted marked variations in the 
size of the air vesicles, which might be smaller than a millet seed or as large as a cherry stone or haricot. 
Vesicles of the latter size were produced by the coalescence of adjacent air spaces following rupture of 
the alveolar walls. Emphysema generally develops between the ages of 45 and 60 as a component of 
COPD in smokers
56
, but lung destruction has also described in other non-smoking-related disorders.  
Pathogenesis The pathogenesis of emphysema is driven by three distinct processes: 1) chronic exposure 
to inhaled toxic agents (mainly cigarette smoke) leads to inflammatory cell recruitment in the terminal 
airspaces; 2) these inflammatory cells release proteases that destroy the extracellular matrix of the lung; 
3) ineffective repair of elastin and other extracellular matrix components leads to development of 
emphysema.
57
 
The inflammatory response in emphysema is characterized by the activation of innate and adaptive 
processes. Indeed, the alveolar spaces are infiltrated by neutrophils, macrophages and lymphocytes, 
which cause the release of potentially destructive proteolytic enzymes and the damage of alveolar-
capillary cells. Production of proteases is not restricted to inflammatory cells: structural cells such as 
epithelial and endothelial cells are also able to produce proteases.
58,59
 As described above, innate 
immunity is based on pattern recognition receptors that recognize structures, such as LPS and endogenous 
ligands; activation of TLR4 by LPS stimulate production of cytokines and ROS, involved in pathogenesis 
of emphysema, as demonstrated by several experimental studies: for example, overexpression of TNF in 
mice lung is able to cause emphysema.
60
 In addition to inflammation, oxidative stress deriving from 
cigarette smoke inhalation plays an important role in pathogenesis of emphysema: the major consequence 
is the activation of the transcription factor NF-kB, which activates proinflammatory cytokine 
transcription.
61,62
 Thus, oxidant damages and lung inflammation are synergistically responsible for the 
increased alveolar destruction and tissue repair defects. 
In the lung, elastin fibers organize into a dense network around capillaries; loss of the alveolar septal 
scaffold after enzymatic degradation of matrix proteins induces airspace enlargement. Moreover, elastin 
fragments are chemotactic and can attract additional inflammatory cells to sites of injury, generating a 
vicious cycle.
63
  Emphysema leads to a progressive decline in the alveolar surface area available for gas 
exchange. Furthermore, loss of alveoli causes airflow limitation because of a decrease in elastic recoil and 
airflow limitation. Moreover, loss of the alveolar supporting structure leads to airway narrowing, which 
further limits airflow. 
13 
 
Protease-antiprotease balance The protease-antiprotease hypothesis and the concept that an excess of 
proteolytic activity can lead to lung destruction are confirmed by clinical and experimental studies.  
In 1964, Laurell and Eriksson described, for the first time, the association between 1-protease inhibitor 
deficiency and pulmonary emphysema.
64
 Moreover, experimental studies conducted by Gross
65-66
 showed 
that instillation into the lungs of enzymes with elastolytic activity induced emphysema and that 
proteolytic enzymes lacking the ability to degrade elastin did not cause emphysema, confirming 
hypothesis deriving from clinical observations. Several enzymes with elastolytic activity contribute to the 
development of emphysema, as observed in the lung of COPD patients
67,68
: neutrophil elastase, 
chymotrypsin, proteinase 3,  metalloproteases, cysteine proteases.
69,70
 Inhibitors of these enzymes are also 
present in the normal lung, thus expanding the concept of protease-antiprotease balance. This balance 
could be modified by several mechanisms in addition to a congenital deficiency of an antiprotease. An 
inflammatory response could lead to the increased release of proteases, as reported in the lower 
respiratory tract of patients with COPD, and the amount of elastase in the lower respiratory tract has been 
correlated with the severity of emphysema. Similarly, levels of matrix metalloprotease (MMP9 and 
MMP12) are increased in COPD.
68,71,72
 
Antiproteases, including 1-protease inhibitor, are susceptible to oxidation. Oxidation of the methionyl 
residue at the active site of 1-protease inhibitor blocks protein activity.73 As a result, smokers with an 
inflammatory response may develop an acquired form of 1-protease inhibitor deficiency.74 Probably, 
tissue destruction results from the integrated activity of multiple proteases, indeed there are important 
interactions between the various classes of proteases. First, both cathepsins and metalloproteases are able 
to inactivate serine protease inhibitors by proteolysis.
70,75
 Similarly, serine proteinases can degrade tissue 
inhibitors of matrix metalloprotease (TIMPs).
76
 Thus, these classes of proteases are capable of alter 
relative proteolytic-antiproteolytic balance by affecting inhibitors of other classes. In addition, 
metalloproteases are generally released as inactive forms
70
 and serine proteases are able to activate these 
proenzyme. Thus, serine proteases may lead to tissue destruction by activating metalloprotease cascades. 
Proteases likely contribute to the pathogenesis of COPD by several mechanisms in addition to destruction 
of the extracellular matrix. In this context, the proteolytic cleavage of elastin by MMPs generates peptides 
that are potent chemoattractants for macrophages.
77
 MMPs, moreover, may play a role in the activation of 
other cytokines, including TGF-β78 and TNF79 Neutrophil elastase can directly stimulate fibroblast 
contraction
80
  which contribute to airways narrowing. Furthermore, neutrophil elastase can induce 
activation of the epidermal growth factor (EGF) receptor and leads to goblet cell metaplasia.
81
 
Cigarette smoke contains approximately 6,000 chemical compounds and many of these are highly 
reactive oxidant species. Moreover, the inflammatory response typically generates oxygen-free radicals 
that can lead to tissue damage. In defense against oxidant damage, several endogenous antioxidants are 
present in the lower respiratory tract. This has led to an oxidant-antioxidant hypothesis analogous to that 
of the protease-antiprotease hypothesis.
82
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Fig. 3 Effects of smoking on emphysema: cigarette smoke induces neutrophils and macrophages recruitment 
in the lung, with consequent increased release of proteolytic enzymes. This condition causes progressive 
destruction of the lung parenchyma, resulting in chronic activation of cellular repair processes and airway 
remodelling. Source http://www.helpmedicose.com/emphysema/ 
Classification There are three morphological types of emphysema: 
 Centriacinar (or centrilobular) emphysema begins in the respiratory bronchioles and spreads 
peripherally. This form is associated with chronic cigarette smoking and predominantly involves 
the upper half of the lungs. 
 Panacinar emphysema destroys the entire alveolus uniformly and is predominant in the lower 
half of the lungs. This phenotype is observed in patients with homozygous  1-antitrypsin 
deficiency.  
 Paraseptal (or distal acinar) emphysema preferentially involves the distal airway structures, 
alveolar ducts and alveolar sacs. The process is localized around the septae of the lungs or pleura. 
Although airflow frequently is preserved, the apical bullae may lead to spontaneous 
pneumothorax; moreover, giant bullae occasionally cause severe compression of adjacent lung 
tissue.
83
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1.3.3 LUNG REMODELLING 
Airway remodelling is defined as an alteration in size, mass or number of tissue structural components, 
leading to thickening of bronchial wall, occurring in response to irritant agents and/or inflammation.
84
 In 
COPD, remodelling may occur in response to smoking-induced damage to the airways and it is 
characterized by large and small airway wall thickening
51
, metaplasia of the epithelium, loss of epithelial 
cilia, increase in goblet cells size and number, submucosal gland and smooth muscle 
hypertrophy/hyperplasia.
85,86
 
Epithelial changes and goblet cells hyperplasia The epithelial response to inhaled noxious compounds 
represents attempts by the bronchial epithelium to protect itself and repair the injury caused by toxic 
factors, as cigarette smoke.
87
 The epithelium is a site of inflammation which shows altered permeability 
and is the source of a number of growth factors and cytokines which modulate inflammatory processes 
and remodelling pathways below the basement membrane.
88
 Cigarette smoke induces the release of IL-
1, IL-8 and granulocyte colony-stimuling factor (G-CSF) from bronchial epithelial cells through 
oxidative pathways,
89
 inducing a neutrophil and monocytes chemotactic activities.
90
 The normal 
pseudostratified ciliated epithelium is replaced by goblet cells and, in more severe disease, by squamous 
metaplasia, which is the reversible replacement of the columnar epithelium by squamous epithelium. In 
addition, there is associated hypertrophy of mucous glands. These anatomical changes are associated with 
alterations in the expression of mucin genes. Goblet cell hyperplasia is more pronounced in smokers with 
COPD than in those without COPD;
91
 these changes, therefore, lead to the production of mucus that is 
abnormal in quality and increased in quantity and, at the same time, mucociliary clearance is impaired
92
, 
contributing to increase morbidity and mortality.
93 
The increase in mucus production and reduction in 
mucociliary clearance caused by cigarette smoking represent an innate host defence response to 
exogenous injuries. The biochemical mechanisms and cellular processes responsible for alteration in 
epithelial cell populations are incompletely defined. However, inflammatory mediators, including 
proteases and oxidants, are able to have effects on epithelial cells. Goblet cell hyperplasia may involve 
the activation of EGF-receptor, which may be upregulated by oxidants in cigarette smoke and release of 
cytokines, such as TNF and IL-8.94,95 Activation of the EGF-receptor, which may take place either by 
direct ligand activation or by non-ligand-mediated activation through either oxidant
96
 or proteolytic 
pathways
81
, can lead to altered mucin gene expression. EGF-receptor activation also appears to be a key 
process in goblet cell metaplasia in animal models.
97 
Smooth muscle A significant increase in airway smooth muscle in small airways of patients with COPD 
has been reported in several studies
98-99
 and the amount of airway smooth muscle has been inversely 
correlated with lung function (FEV1% predicted).
100
 The amount of airway smooth muscle was increased 
by nearly 50% in patients with more sever COPD.
51
 Although the airway smooth muscle mass is 
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increased, it is unknown whether this is caused by an increased number of airway smooth muscle cells, an 
increase in airway smooth muscle cell size or both.  
Airway smooth muscle cells have contractile properties, but also are able to produce and release 
cytokines, chemokines, growth factors and proteases
101,102
 participating in the inflammatory and 
remodelling mechanisms.
103
 
Fibrosis It is likely that the process responsible for lung fibrosis resembles the mechanism responsible for 
fibrosis in other chronic disorders. In this context, TGF plays a central role, particularly in wound 
healing.
104,105
 It is a potent activator of fibroblasts, converting them to a myofibroblast-like phenotype, 
through the increase in SMA expression106 and inducing the production of extracellular matrix.107,108 
TGFβ also stimulates fibroblast recruitment109 and augments the ability of fibroblasts to contract and 
reduce their surrounding extracellular matrix.
110
 TGFβ activates a receptor that functions as a 
serine/threonine kinase and phosphorylates Smad proteins, particularly Smad-2 and Smad-3, although 
other signaling pathways may also play a role
104; in particular, Smad-3 signaling appears to be key in 
both wound healing and fibroblast activation.
105,107-111 
 
In addition to TGFβ, a variety of other cytokines likely present in the lung in COPD can also modulate 
fibroblast activity. Increased levels of the Th2 cytokines IL-4 and IL-13, which can stimulate 
fibroblasts
112,113
 have been reported in tissues in COPD.
114
 Imbalance between tissue destruction and 
tissue repair can also contribute to the development of emphysema; cigarette smoke can inhibit fibroblast 
repair responses
115,116
, suggesting that smoke may shift the balance toward the development of 
emphysema by impeding repair as well as by augmenting destruction.  
Modulation of the fibrotic response in the small airways could have an effect in modifying the natural 
history of COPD. 
Multiple roles of TGF in airway remodelling As mentioned above, TGF has multiple effects in the 
same cell type and in different cells, depending on microenviromental and cellular conditions. TGF 
induces apoptosis in airway epithelial cells and is involved in the regulation of adhesion properties of 
epithelial cells, leading to damage of the epithelial cell layer.
117
 Moreover, TGF has a role in 
hyperproliferation of goblet cells and hypersecretion of mucus.
118-119
 The most important effect of TGF 
is the inducing action on fibroblast proliferation, differentiation and extracellular matrix protein 
production. Furthermore, TGF contributes to enhance the proliferation of airway smooth muscle cells 
and is involved in the abnormal proliferation of blood vessels.
117
 Therefore, it is evident how all these 
properties of TGF confirm its key role in the exacerbation of airway remodelling. 
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Fig. 4 Multiple roles of TGFb in lung remodelling.  
Source: Makinde et al. Immunol Cell Biol 2007
117
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2. COPD  THERAPY  
2.1 CLINICAL FEATURES 
Patients often ignore symptoms, modify their lifestyle to minimize dyspnea and ignore cough and sputum 
production. Typically they present with a combination of signs and symptoms of chronic bronchitis, 
emphysema and reactive airway disease, including: 
 productive cough that worsens in the mornings and produces a small amount of colorless sputum; 
 breathlessness which is the most significant symptom, but it usually does not occur until the sixth 
decade of life. By the time the FEV1 has fallen to 50% of predicted, the patient is usually breathless upon 
minimal exertion. In fact, the FEV1 is the most common variable used to grade the severity of COPD, 
although it is not the best predictor of mortality; 
 wheezing which may occur in some patients, particularly during exertion and exacerbations. 
According to the 2011 guidelines, a history of more than 40 pack-years of smoking was the best single 
predictor of airflow obstruction; however, the most helpful information was provided by a combination of 
the following 3 signs
120
: 
 self-reported smoking history of more than 55 pack-years; 
 wheezing on auscultation; 
 self-reported wheezing. 
If all 3 signs are absent, airflow obstruction can be nearly ruled out. With disease progression, intervals 
between acute exacerbations become shorter and each exacerbation may be more severe.  
COPD is now known to be a disease with systemic manifestations and the quantification of these 
manifestations has proved to be a better predictor of mortality than lung function alone. Many patients 
with COPD may have decreased fat-free mass, impaired systemic muscle function, osteoporosis, anemia, 
progressive exercise intolerance, alteration in mental status, pulmonary hypertension and even left-sided 
heart failure. Depression is not uncommon in subjects with COPD.
121
  
2.2 STAGES OF COPD 
The GOLD classifications are the main method used to describe the severity of COPD. GOLD classifies 
people with COPD based on their degree of airflow obstruction. The airflow limitation is measured 
during pulmonary function tests: when blowing out forcefully, people with normal lungs can exhale most 
of the air in their lungs in one second. Pulmonary function tests measure this and other values and are 
used to diagnose COPD and its severity. The volume in a one-second forced exhalation is called the 
forced expiratory volume in one second (FEV1), measured in liters. The total exhaled breath is called the 
forced vital capacity (FVC), also measured in liters. In people with normal lung function, FEV1 is at least 
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70% of FVC. Because of lung damage, people with COPD take longer to blow air out; therefore, an 
FEV1 less than 70% of FVC can make the diagnosis of COPD in someone with compatible symptoms 
and history.
1
 
Classifications are then used to describe the severity of the obstruction or airflow limitation. The lower 
their FEV1, the worse a person's airflow limitation, thus as COPD progresses, FEV1 tends to decline. 
GOLD introduced four categories of severity for COPD, based on the value of FEV1: 
STAGE FEV1/FVC FEV1 
Stage I       Mild COPD FEV1/FVC<0.70 FEV1≥ 80% normal 
Stage II     Moderate COPD FEV1/FVC<0.70 FEV1 50-79% normal 
Stage III    Severe COPD FEV1/FVC<0.70 FEV1 30-49% normal 
Stage IV    Very Severe COPD FEV1/FVC<0.70 FEV1 <30% normal, or <50% normal with 
chronic respiratory failure present 
Table 1. GOLD classification based on FEV1/FVC and FEV1 values. 
2.3 COPD TREATMENT  
The goal of COPD treatment is to improve a patient’s functional status and quality of life by preserving 
optimal lung function, improving symptoms and preventing the recurrence of exacerbations. Currently, no 
treatments aside from lung transplantation have been shown to significantly improve lung function or 
decrease mortality. Once the diagnosis of COPD is established, it is important to educate the patient about 
the disease and to encourage his active participation in therapy. 
Approaches to management include recommendations such as those provided by GOLD: 
 Stage I (mild obstruction): reduction of risk factors (influenza vaccine, smoking cessation); short-
acting bronchodilator as needed. 
 Stage II (moderate obstruction): reduction of risk factors (influenza vaccine, smoking cessation); 
short-acting bronchodilator as needed; long-acting bronchodilator; cardiopulmonary rehabilitation. 
 Stage III (severe obstruction): reduction of risk factors (influenza vaccine, smoking cessation); 
short-acting bronchodilator as needed; long-acting bronchodilator; cardiopulmonary rehabilitation; 
inhaled glucocorticoids if repeated exacerbations. 
 Stage IV (very severe obstruction or moderate obstruction with evidence of chronic respiratory 
failure): reduction of risk factors (influenza vaccine, smoking cessation); short-acting bronchodilator 
as needed; long-acting bronchodilator; cardiopulmonary rehabilitation; inhaled glucocorticoids if 
repeated exacerbation; long-term oxygen therapy; consider surgical options such as lung volume 
reduction surgery and lung transplantation. 
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Oral and inhaled medications are used for patients with stable disease to reduce dyspnea and improve 
exercise tolerance. Most of the medications used are directed at the following four potentially reversible 
causes of airflow limitation in a disease state that has largely fixed obstruction: 
 Bronchial smooth muscle contraction 
 Bronchial mucosal congestion and edema 
 Airway inflammation 
 Increased airway secretions 
Inadequate nutritional status associated with low body weight in patients with COPD is associated with 
impaired pulmonary status, reduced diaphragmatic mass, lower exercise capacity and higher mortality 
rates. Nutritional support is an important part of comprehensive care in patients with COPD
122
. 
2.3.1 BRONCHODILATOR TREATMENT 
Bronchodilator drugs are the key aspect of COPD treatment regimen. They are able to dilate airways, 
increasing airflow and decreasing dynamic hyperinflation. Nevertheless, these drugs provide symptomatic 
relief but do not alter disease progression or decrease mortality. 
2-agonist bronchodilators activate specific 2-adrenergic receptors on the surface of smooth muscle cells, 
which increases intracellular cyclic adenosine monophosphate (cAMP) and smooth muscle relaxation. 
Even patients who have no measurable increase in post-bronchodilator expiratory airflow may benefit 
from treatment with 2-agonists. The inhaled route is preferred because it minimizes adverse systemic 
effects.  
Anticholinergic drugs compete with acetylcholine for postganglionic muscarinic receptors, inhibiting 
bronchomotor tone and inducing bronchodilation. They block vagally mediated reflex arcs that cause 
bronchoconstriction. These agents are poorly absorbed systemically and are relatively safe.  
Historically, 2-agonists were considered first line and anticholinergics were added as adjuncts. Studies 
have shown that combination therapy results in greater bronchodilator response and provides greater 
relief. Monotherapy with either agent and combination therapy with both are acceptable options. 
Generally, long-acting bronchodilators are more beneficial than short-acting ones.
123-124
 
Guidelines recommend combination therapy involving two long-acting bronchodilators with differing 
modes of action in patients whose COPD is not sufficiently controlled with monotherapy
1
. As mentioned, 
airway smooth muscle relaxation can be achieved via two main routes: inhibition of acetylcholine 
signaling via muscarinic M3 receptors on airway smooth muscle with a muscarinic antagonist, or 
stimulation of β2-adrenoceptors with a β2-agonist.
125,126
 Targeting these two mechanisms of 
bronchoconstriction has the potential to optimize the bronchodilator response without increasing the dose 
of either component. The interaction between the two systems has yet to be fully elucidated; however, β2-
agonists can amplify the bronchial smooth muscle relaxation directly induced by the muscarinic 
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antagonist by decreasing the release of acetylcholine via modulation of cholinergic neurotransmission. 
Additionally, muscarinic antagonists have been demonstrated to augment β2-agonist-stimulated 
bronchodilation by reducing the bronchoconstrictor effect of acetylcholine in preclinical models.
125
  
Short-acting muscarinic antagonist (SAMA) plus short-acting β2-agonist (SABA) The concept of 
adding a muscarinic antagonist to a β2-agonist is not new. A fixed-dose combination of the short-acting 
agents ipratropium and albuterol and of fenoterol and ipratropium provides significant benefits over 
monotherapy with either component.
127-128
 Additionally, dual bronchodilation with ipratropium and 
albuterol resulted in a consistently longer response and more patients achieved a pre-specified response 
level (12-15%) in FEV1 with the combination compared to individual components
127-129
, with an 
equivalent or improved safety profile. 
Long-acting muscarinic antagonist (LAMA) plus long-acting β2-agonist (LABA) Relatively few 
studies have examined the combination of LAMAs and LABAs. Several randomized controlled trials 
have reported improved lung function for tiotropium plus formoterol versus tiotropium alone.
130,131
 Some 
trials have also identified significant improvements in symptom scores.
132-133
 A recent meta-analysis 
confirmed the benefits of tiotropium plus formoterol on average FEV1 and Transition Dyspnea Index 
(TDI).
134
 Currently available data on tiotropium plus salmeterol are conflicting: initial investigations 
indicated the benefits of tiotropium plus salmeterol versus either monotherapy alone, while suggesting co-
administration of once-daily salmeterol plus tiotropium was inadvisable, due to the shorter duration of 
bronchodilation provided by salmeterol.
135
 The Canadian Optimal Therapy of COPD trial investigated the 
impact of tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus salmeterol/fluticasone 
on clinical outcomes in 449 patients with moderate to severe COPD.
136
 Tiotropium plus 
salmeterol/fluticasone (but not tiotropium plus salmeterol) statistically improved lung function and 
quality of life and reduced the number of hospitalizations for exacerbations compared to tiotropium plus 
placebo.
136
 A more recent study, however, demonstrated significant improvements in FEV1 with 
salmeterol once or twice daily plus tiotropium.
137
 
Tiotropium plus indacaterol has been demonstrated to improve lung function and inspiratory capacity, as 
well as providing a further reduction in use of rescue medication.
138
 These data confirm that combination 
therapy has the potential to improve outcomes versus monotherapy.  
The safety profiles of both LAMAs and LABAs are well understood; given that both muscarinic 
antagonists and β2-agonists can have a detrimental effect on the cardiovascular system
139,140
, these adverse 
events need to be monitored carefully in development programs for combination products. Initial results 
suggest that the cardiovascular safety profile of glycopyrronium plus indacaterol is similar to placebo, 
with no clinically significant differences observed versus placebo
141
 and, to date, no safety concerns have 
been identified with tiotropium plus olodaterol.
142
 Free combinations of LAMA/LABA also seem well 
tolerated. No differences in blood pressure and pulse rate were observed with tiotropium plus salmeterol 
versus single-agent therapies.
137
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2.3.2 MANAGEMENT OF INFLAMMATION  
Inflammation plays a significant role in the pathogenesis of COPD. Systemic and inhaled corticosteroids 
attempt to temper this inflammation and positively alter the course of disease. The use of systemic 
steroids in the treatment of acute exacerbations is widely accepted and recommended, given their high 
efficacy. A meta-analysis concluded that oral and parenteral corticosteroids significantly reduced 
treatment failure and the need for additional medical treatment and that they increased the rate of 
improvement in lung function and dyspnea over the first 72 hours.
143
 On the other hand, the use of oral 
steroids in persons with chronic stable COPD is widely discouraged, given their adverse effects which 
include hypertension, glucose intolerance, osteoporosis, fractures and cataracts. A Cochrane review 
showed no benefit at low-dose therapy and short-lived benefit with higher doses (>30 mg of 
prednisolone).
144
 
Inhaled corticosteroids (ICS) provide a more direct route of administration to the airways and, similar to 
other inhaled agents, are only minimally absorbed. Consequently, the systemic adverse effects of these 
medications at standard doses are negligible. Despite the theoretical benefit, the current consensus is that 
inhaled corticosteroids do not decrease the decline in FEV1, although they have been shown to decrease 
the frequency of exacerbations and improve quality of life for symptomatic patients with a FEV1 of less 
than 50%.
145
 The 2013 ICSI (Institute for Clinical Systems Improvement) guidelines conclude that 
inhaled steroids are appropriate in patients with recurrent exacerbations of COPD.
146
 Inhaled 
corticosteroids are not recommended as monotherapy and should be added to a regimen that already 
includes a long-acting bronchodilator. The TORCH trial (TOwards a Revolution in COPD Health) 
showed that a combination of an inhaled corticosteroid and a long-acting 2-agonist was more beneficial 
than inhaled corticosteroids alone.
147
 These data suggest that in patients with COPD, inhaled 
corticosteroids should be used only in conjunction with a long-acting -agonists. However, patients 
treated with inhaled corticosteroids were noted to have an increased rate of pneumonia. Despite the 
possible increased risk of pneumonia associated with inhaled corticosteroids, a retrospective cohort study 
showed that in patients with COPD hospitalized with pneumonia, prior use of inhaled corticosteroids was 
actually associated with decreased mortality and less mechanical ventilation.
148
 
Nonsteroidal anti-inflammatory medications have not been shown conclusively to have any benefit in 
COPD. No response has been shown to medications targeting IL-8 and TNF. Leukotriene inhibitors 
commonly used in asthma have also not proven to be beneficial in COPD. However, macrolide antibiotics 
have been shown to have anti-inflammatory effects in the airways of COPD patients. More specifically, 
azithromycin has been shown to improve the phagocytic function of pulmonary macrophages and to be a 
potent anti-inflammatory.
149
 
Combination of corticosteroids and bronchodilators The combination of LABA and ICS is the most 
common in use for both COPD and asthma. The physiological and clinical benefits of LABAs have 
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been shown to be enhanced when administered in conjunction with ICS.
150
 ICS and LABAs 
combination have been shown to improve lung function, symptoms and health status, and they 
reduce exacerbations in patients with moderate to severe COPD.
151-152 
Results of a recent meta-
analysis showed that ICS/LABA did not decrease the number of severe exacerbations, respiratory 
mortality and cardiovascular mortality compared with LABA monotherapy.
153
 This meta-analysis 
showed that the superior FEV1 achieved with the ICS/LABA compared with LABA monotherapy 
was able to increase the frequency of pneumonia. This is in conflict with an earlier analysis of the 
same database that found that ICS/LABA combination therapy was superior to LABA monotherapy 
for exacerbation frequency reduction.
154
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3. ANIMAL MODELS OF COPD 
COPD humans studies are limited to morphological evaluations of lung biopsies or in vitro research. 
Thus, the development of animal models is of great importance for analysing molecular mechanisms, 
histological and functional alterations, commonly observed in patients with COPD, and for evaluating 
new therapeutic approaches.  
To date, many species have been used, including rodents, guinea-pigs, monkeys and sheep.
155-156
 Mice 
offer the greatest ability to explore pathogenesis of COPD, because of the low cost, the ability to produce 
animals with genetic modifications that are useful to investigate specific pathways, the big amount of 
antibody probes and the availability of numerous occurring mouse strains with different reactions to 
smoke exposure. In mice, features of human COPD can be modelled by exogenous administration of 
proteases, chemicals, particulates and cigarette smoke exposure
155,157-158
. Regardless of the method of 
exposure, many of the hallmark features of human COPD, as chronic lung inflammation, impaired lung 
function, emphysema, mucus hypersecretion, small airway thickening, lymphoid aggregates can be 
mimicked in the smoking murine model. Nevertheless, there is no COPD animal model that replicates all 
the phenotype observed in humans. 
 
Indicator Human features Experimental 
approaches 
History of exposure to 
risk factors  
Tobacco smoke 
Occupational dusts and chemicals  
Indoor/outdoor air pollution 
Exposure-based experimental 
protocol 
Chronic lung 
inflammation 
Elevated levels of macrophages, neutrophils and T-
cells and cytokines in lung 
Assessment of airway cytokine 
levels  
Airflow obstruction Decrease in FEV1 Lung function test 
Hypersecretion Chronic sputum production Morphological assessment of 
hypersecretion 
Emphysema  Progressive impairment of lung function Morphological assessment of 
airspace enlargement and lung 
function test 
Airway remodelling Bronchial wall thickening Morphological assessment of 
bronchial wall diameter 
 
Table 2. Indicators for COPD observed in human that should ideally be present in animal models and 
available for analysis. 
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3.1 EXPOSURE TO TOXIC OR IRRITANT AGENTS 
Cigarette smoke Most animal models requires the exposure to cigarette smoke, the main risk factor. 
Exact comparisons of findings from groups are difficult because of different types of cigarettes, doses, 
instruments, exposure protocols and variety of mouse strains. A number of factors must be considered to 
the design of cigarette smoke-induced models of COPD. The method of smoke production and exposure 
is a critical factor. Mainstream smoke refers to the smoke produced and drawn back through a cigarette 
by the act of inhalation or puffing. This type of exposure occurs in active smokers. Sidestream smoke 
refers to the smoke produced passively from the burning end of a cigarette that escapes into the 
surrounding atmosphere before being inhaled. Exposure to sidestream and exhaled mainstream smoke 
occurs during passive smoke exposure. Although both types of smoke have the same chemical 
composition, there is a considerable difference in the relative concentration of components
159,160
, but some 
studies
159
 suggested that the two types of smoke may not generate large differences in COPD phenotype. 
At present, two exposure systems are used: whole-body and nose-only. Both systems have been used 
widely to provide important insights into COPD pathogenesis. Nose-only system allows to reduce the 
potential confounding ingestion of nicotine, tar and other chemical agents by animals from their fur and to 
generate intermittent smoke exposures mimicking the puff profile of human smokers. 
The inflammatory response induced by cigarette smoke occurs in two phases: an acute phase 
characterized by neutrophils and a chronic phase (after 2-4 weeks of exposure) with neutrophils, 
macrophages and lymphocytes permeation.
161,162 
Churg et al.
163
, in a murine model of acute exposure (4 
cigarettes for 1 hour), observed that the inflammation is associated with NF-kB and TNF activation, 
responsible for the up-regulation of E-selectin. Vlahos et al.
164
 demonstrated that mice fully exposed to 
cigarette smoke for 4 days showed significant high levels of macrophages, neutrophils and proteases in 
BAL, besides the increased gene expression of inflammatory cytokines. Chronic application of the same 
protocol  (3-6 months) was able to induce a persistent airway inflammation accompanied by emphysema. 
First studies of chronic exposure to smoke (6 months) have shown an increase in goblet cell number, a 
thickening of bronchial wall, a reduction in alveolar attachments and the formation of lymphocyte 
aggregates around bronchial wall, as observed in humans.
155
  
Lungs of mice and rats exposed to smoke for 6 hours/day, 5 days/week for 7 or 13 months, showed 
significant differences in two species: bronchial alterations observed in mice at the thirteenth month of 
treatment are greater than those observed in rats; in addition, inflammatory infiltrate in mice showed a 
higher level of neutrophils, indicating that exposure to tobacco smoke induces a COPD-like phenotype 
more significant in mice despite of rats.
165
  
Further studies have shown that cigarette smoking promotes the release of proteolytic enzymes by 
inflammatory cells with imbalance between the levels of protease and antiprotease, the process 
underlying the development of pulmonary emphysema.
166
  
Experimental models described so far include several disadvantages:  
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 exposure to cigarette smoke for several months, with high costs;  
 phenotype obtained generally equivalent to early or moderate stages of COPD;  
 difficulty to reproduce emphysema or significant remodelling, typical of severe stages of COPD;  
 after smoking cessation, emphysema is not progressive and goblet cell metaplasia regresses, 
unlike what was observed in advanced stages of COPD, where structural alterations progress 
even after smoking cessation.
155
  
Bacterial lipopolysaccharide Lipopolysaccharide (LPS) is a component of the outer wall of gram-
negative bacteria, also present as a contaminant in the smoke of cigarette, air pollution and organic dusts. 
LPS administration induces an inflammatory response with increased levels of neutrophils and pro-
inflammatory cytokines (TNF, IL-1) in BAL, enhanced production MMP9 and MMP12 and decreased 
lung function. Furthermore, it has been observed that exposure to LPS induces bronchial wall thickening, 
hyperplasia of goblet cells, collagen deposition.
167
 LPS administration may occur through direct 
instillation into nasal cavities or intratracheal or intravenous injection and inhalation. Exposure by 
inhalation is the most widely used, since it induces a greater inflammatory response compared to 
intratracheal instillation, because aerosolized LPS distributes uniformly throughout the lung, while by 
instillation, distribution is irregular and can cause a significant inflammatory response exclusively where 
LPS is deposited.
168
 Thus, LPS administered either alone or in combination with cigarette smoking is 
useful to induce a strong bronchial inflammation, in order to mimic events of exacerbations that 
commonly occur in concomitance with respiratory infections.
155
 
Sulfure dioxide, nitrogen dioxide, oxidants and particulate Sulfur dioxide (SO2) is an irritant gas used 
to induce, in rodent or guinea pigs, lung damages. Exposure to high levels (200 to 700 ppm for 4-8 
weeks) is able to trigger pulmonary inflammation, with increased polymorphonuclear and mononuclear 
inflammatory cells in airways, mucus overproduction and goblet cell hyperplasia. Mechanisms underlying 
this effect have not yet been clarified; however, the interruption of exposure to SO2 leads to total 
remission of inflammation within 1 week.
166
  
A brief inhalation to nitrogen dioxide (NO2) induces an initial response with extensive tissue damage, 
followed by a late phase in which repair processes are activated. The exposure of rats to 10 ppm of NO2 
for more than 24 hours induce ciliar damages and hypertrophy of bronchial epithelium. A concentration 
of 15 ppm for 7 days leads to an increased mitochondrial activity and oxygen consumption in the airways. 
Doses of 50-150 ppm (mg/m
3
 94-282) can determine significant lung injury, edema, hemorrhage, pleural 
effusion and death. Exposure to ozone has a toxic effect on the respiratory tract because of the strong 
oxidative stress that induces increased production of cytokines and decreased lung function. Some 
experimental protocols require the use of silica, coal dust and ultrafine particles, commonly found in air 
pollution derived by combustion. Inhalation of these substances causes an intense oxidative stress that 
results in pulmonary emphysema. Exposure to diesel exhaust particles (DEP), known for its high 
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oxidizing power, is another type of approach used in some models of chronic inflammation of the 
airways. A long-term treatment can determine the onset of cancer.
166
 
3.2 TREATMENT WITH PROTEASES 
Single intratracheal administration of proteolytic enzymes, such as human neutrophil elastase, porcine 
pancreatic elastase or papain is sufficient to induce morphological changes such as emphysema. Porcine 
pancreatic elastase is the most used because of the lower cost and greater availability compared to human 
neutrophil elastase.
155
 Proteases promote up-regulation of inflammatory cytokines (TNF, IL-1, IL-6 
and IL-8) resulting in lesions of lung parenchyma, loss of collagen and elastin and consequent 
enlargement of the airspaces and emphysema. The advantage of these models is that a single intratracheal 
administration of protease leads to rapid and significant changes, although less significant than those 
obtained with exposure to cigarette smoke.
155
 
3.3 GENE-TARGETING APPROACHES 
Genetically-altered monogenic and polygenic models to mimic COPD have been developed in recent 
years using modern techniques of molecular biology.
156,169
 Gene-depletion and gene-overexpression in 
mice provide a powerful technique to identify the function and role of distinct genes in the regulation of 
pulmonary homeostasis in vivo. Mice lacking elastin were generated since destruction of alveolar elastic 
fibers is implicated in the pathogenic mechanism of emphysema and elastin is a major component of the 
extracellular matrix. It was shown that these animals have an arrest in the development of terminal 
airways accompanied by fewer distal air sacs that are dilated with attenuated tissue septae.
170
 Also, 
deficiency of the microfibrillar component fibulin-5 and platelet derived growth factor A (PDGF-A) leads 
to airspace enlargement.
171,172
 PDGF-A (-/-) mice lack lung alveolar smooth muscle cells, exhibit reduced 
deposition of elastin fibers in the lung parenchyma and develop lung emphysema due to a complete 
failure of alveogenesis.
173
 Fibroblast growth factors are known to be essential for lung development. Mice 
simultaneously lacking receptors for FGFR-3 and FGFR-4 have an impaired alveogenesis with increased 
collagen synthesis.
174
 
A further mechanism to induce emphysema-like lesions is to expose developmentally normal genetically-
modify animals to exogenous noxious stimuli such as tobacco smoke. This also allows to identify 
potential molecular mechanisms involved in the pathogenesis of COPD. Using MMP12 gene depletion 
studies it was shown that in contrast to wild type mice, the lung structure of MM12 gene-depleted animals 
remains normal after long term exposure to cigarette smoke.
175
 
Gene-targeting techniques display very useful tools to examine potential molecular mechanisms 
underlying human COPD.  
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4. AIMS OF THE STUDY 
 Validation of a new murine model of COPD  
In vivo models of airway inflammation and lung damage are the preferred preclinical system for 
evaluating mechanisms and mediators related to COPD. As mentioned above, the major risk factor, acute 
and/or chronic exposure to cigarette smoke (CS), is the model most used.
161,176
 Wagner et al.
177
 identified 
a model of airway inflammation and hypersecretion exposing rats to different levels of SO2; other models 
use acute NO2 exposure
178
 or administration of elastolytic enzymes, including pancreatic elastase, 
neutrophil elastase and proteases, which results in air-space enlargement.
179,180
 Moreover, in recent years 
models to mimic COPD have been developed using modern techniques of molecular biology that induce 
lung emphysema secondary to the failure of alveolar septation.
172
 However, these approaches are able to 
reproduce a limited amount of COPD features, such as emphysema and chronic inflammation. The focus 
should also be on crucial processes in the progression of the disease, such as bacterial exacerbations and 
remodelling mechanisms.  
In a first part of this work, the aim was to reproduce an innovative murine model of COPD through the 
exposure to a combination of three main risk factors: cigarette smoke, LPS to mimic bacterial 
exacerbations, and particulate matters with a diameter less 10 µm from environment. A time course was 
performed by sacrificing animals at the first, third and sixth week of exposure to monitor progression of 
lung injury.  
Anti-inflammatory and bronchodilator therapy in the early stage of COPD 
As observed in previous studies on murine model, exposure to risk factors induces a peak of inflammation 
in the first stage of treatment, responsible for the following activation of remodelling pathways. The aim 
of this study was to evaluate effects of an early treatment with a combination of anti-inflammatory and 
bronchodilator drugs to attenuate the inflammatory processes and subsequent tissue changes. This is in 
contrast to current GOLD guidelines, which provide an anti-inflammatory treatment only in severe stages 
of COPD, when tissue remodelling has already been occurred. The key point of COPD therapy could be 
the attenuation of acute inflammation that occurred in the early stage of pathogenesis, when tissue 
damage is less relevant and bronchial structural changes are still reversible. 
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a) According to current GOLD guidelines, inhaled corticosteroids should be added to a regimen that 
already includes a long-acting bronchodilator in advanced stages of COPD, when tissue remodelling has 
already been occurred. 
b) The hypothesis is that the addition of inhaled corticosteroids to a bronchodilator therapy in early stages 
of pathogenesis could be able to influence the progression of COPD, as tissue damage is less relevant and 
bronchial structural changes are still reversible.  
Pharmacological treatment 
Pharmacological treatment 
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5.METHODS 
5.1 INDUCTION OF COPD  
5.1.1 ANIMALS 
Animals The study protocol was reviewed and approved by the Committee on Ethics in Animal 
Experiments of the Italian National Institutes of Health. Seventy BALB/c male mice (10 weeks of age; 
n=5 for group) were obtained from Charles River Laboratory (Calco, Italy), fed a normal mouse diet 
ad libitum, housed under biosafety level 2 conditions, and cared for according to the standard and 
specific procedures outlined by the Italian National Institutes of Health. 
Animals were divided into 14 groups: 
 Control mice exposed to room air and aerosolized with saline 
 Mice exposed to particulate matter (PM-10) for 1, 3 and 6 weeks 
 Mice exposed to LPS for 1, 3 and 6 weeks 
 Mice exposed to cigarette smoke for 1, 3 and 6 weeks 
 Mice exposed to PM-10, LPS and cigarette smoke for 1, 3 and 6 weeks 
 Mice exposed to PM-10, LPS and cigarette smoke for 6 weeks followed by suspension of 
treatment for 4 weeks. 
At the end of the respective exposures mice were sacrificed under anesthesia with intraperitoneal 
urethane (1.6 g/kg, Sigma-Aldrich, St Louis, MO, USA), bronchoalveolar lavage (BAL) was 
performed and the lungs were removed. Lungs were immediately dissected and then separated into 
individual lobes: one was fixed in 4% buffered formalin, routinely processed and embedded in 
paraffin for histological analysis; the other was frozen in isopentane and stored at –80°C for molecular 
analysis. 
5.1.2 PM-10 EXPOSURE  
Mice were exposed to two different types of particulate matter (PM-10): ERM-CZ100 and ERM-CZ120 
(Sigma-Aldrich, St Louis, MO), containing respectively organic and inorganic fractions. This product was 
certified by the Institute for Reference Materials and Measurements (IRMM). 
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ERM-CZ100 ERM-CZ120 
Benzo[a]anthracene 
Benzo[a]pyrene 
Benzo[b]fluoranthene 
Benzo[j]fluoranthene 
Dibenzo[a,h]anthracene 
Indeno[1,2,3-c,d]pyrene 
Sum of benzo[b]fluoranthene, 
benzo[k]fluoranthene, benzo[j]fluoranthene 
Arsenic 
Cadmium 
Lead  
Nickel 
Table 3. Composition of organic (CZ100) and inorganic (CZ120) fraction of PM-10. 
Mice were treated with 2 mg aerosolized PM-10 (1 mg of ERM-CZ100 + 1 mg of ERM-CZ120, 
diluted in 6 ml of saline) once a day for 5 days/week. The control group was aerosolized with saline 
only. The aerosol was generated with an ultrasonic nebulizer (Flaem, Universal plus) and introduced 
into a Plexiglas chamber box where the mice were placed. 
5.1.3 LPS EXPOSURE  
Aerosolization was conducted by nebulization of LPS (Escherichia coli serotype 026:B6; Sigma-Aldrich, 
St Louis, MO) diluted with saline solution, using an ultrasonic nebulizer (Flaem, Universal plus) and 
introduced to a Plexiglas chamber box where the mice were placed. Animals were treated twice weekly 
with 2.5 mg of LPS (diluted in 6 ml of saline) blown into the chamber box for approximately 20 minutes; 
controls were aerosolized with endotoxin-free saline. 
5.1.4 CIGARETTE SMOKE EXPOSURE  
Mice were exposed to the smoke of 21 cigarettes/day (3 cycles of 7 cigarettes/cycle), for 5 days/week, 
using commercial cigarettes (10 mg tar, 0,8 mg nicotine, 10 mg CO) in a special cage (Tecniplast, 
Buguggiate, Italy). Control mice were exposed to room air. 
The smoke was produced by the burning of a cigarette and was introduced into the chamber with the 
airflow generated by a mechanical ventilator (7025 Rodent Ventilator, Ugo Basile, Biological Research 
Instruments, Comerio, Italy) at a frequency of 25 strokes/minute and a volume of 8 ml/stroke (flow 200 
ml/min). 
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5.2 PHARMACOLOGICAL TREATMENT 
Mice with COPD-like phenotype were treated with different drugs at different times, as described in 
Tables 4-5. Drugs and doses:  
 β2-agonist: 6 ml salmeterol/die (15 µg/ml) 
 Antimuscarinic: 6 ml tiotropium bromide/die (7 µg/ml) 
 Corticosteroid: 6 ml fluticasone furoate/die (43.2 µg/ml) 
Drugs were aerosolized using an ultrasonic nebulizer (Flaem, Universal plus) and introduced to a 
plexiglas chamber box, once a day, for approximately 20 minutes. Control mice were aerosolized only 
with saline. 
 
 
 
Table 4. Mice with COPD-like phenotype were treated with different combination of drugs, starting therapy 
in early stage for some groups and in late phase for others. 
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Group Exposure to smoke, 
PM10 and LPS 
Pharmacological aerosol 
treatment (for 4 weeks) 
Control mice No exposure to risk 
factors 
 
No treatment (n=5)  
 
Mice with COPD-
like phenotype 
Exposure for 5 
weeks 
 
No treatment (n=5)  
Exposure for 9 
weeks 
 
No treatment (n=5)  
 
 
 
Mice with COPD-
like phenotype 
and early 
treatment (started 
at the 1
st
  week of 
exposure to risk 
factors) 
 
 
 
 
Exposure for 5 
weeks 
 
β2 agonist (n=5)  
 
Antimuscarinic (n=5) 
 
Corticosteroid (n=5) 
 
β2 agonist + Corticosteroid (n=5) 
 
Antimuscarinic + Corticosteroid 
(n=5) 
 
β2 agonist + Antimuscarinic + 
Corticosteroid (n=5) 
 
 
 
 
Mice with COPD-
like phenotype 
and late treatment 
(started at the 6
th
  
week of exposure 
to risk factors) 
 
 
 
 
Exposure for 9 
weeks 
 
β2 agonist (n=5) 
 
Antimuscarinic (n=5) 
 
Corticosteroid (n=5) 
 
β2 agonist + Corticosteroid (n=5) 
 
Antimuscarinic + Corticosteroid 
(n=5) 
 
β2 agonist + Antimuscarinic + 
Corticosteroid (n=5) 
 
Table 5. Treatment schedule of mice with COPD-like phenotype. 
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5.3 GENE EXPRESSION 
5.3.1 RNA ISOLATION AND REVERSE TRANSCRIPTION  
Total RNA was purified from the lungs using TRIzol reagent (Life Technologies, Carlsbad, CA). After 
purification, RNA was treated with DNase (DNA-free-Ambion), and cDNA was synthesized with a high-
capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s instructions. 
5.3.2 REAL-TIME PCR  
PCR reactions were performed with cDNA and 100 nM of commercially available target-specific 
Taqman-FAM-labelled probes (Applied Biosystems, USA), using TaqMan Universal PCR Master Mix. 
TaqMan probe/primers specific for 18S (Hs99999901_s1), TGFβ (Mm01176413_m1), αSMA 
(Mm00725412_s1), SphK1, SphK2, S1P3 and CXCL15 were Taqman Assays-on-Demand Gene 
Expression Products. All reagents were from Applied Biosystems. Real-time PCR was carried out using 
ABI PRISM 7000 (Applied Biosystems, Forster City, CA). Gene expression was assessed relative to 18S 
and as a fold change to control using the 2
−ΔΔCt
 method. All PCR assays were performed in duplicate. 
5.4 CYTOKINE LEVELS 
5.4.1 BRONCHOALVEOLAR LAVAGE (BAL)  
The trachea was exposed and cannulated with a needle (20 gauge x 32 mm); lungs were then washed 
three times with sterile saline (0.3 ml, 0.3 ml, 0.4 ml). Liquid samples were centrifuged at 1200 g for 15 
minutes and supernatants were collected at –80°C for ELISA tests. 
5.4.2 ELISA TEST  
Cytokine levels were measured using a mouse ELISA Ready-SET-Go! Kit (TNFα, IL1β, GM-CSF, IL-
10) purchased from eBioscience (San Diego, CA), according to the manufacturer’s recommended 
procedure. Briefly, samples were first placed into 96-well plates which had been coated with a mouse 
monoclonal antibody as a catcher. Following incubation for 2 hours at room temperature, the plate was 
washed five times with phosphate-buffered saline. Biotin-conjugated antibody and avidin–horseradish 
peroxidase were then used to detect the presence and concentration of cytokines; the absorbance at 450 
nm was determined by a microplate reader. The concentration of cytokines in each sample was 
extrapolated from a standard curve, obtained with scalar concentrations of recombinant cytokine, and 
assayed with ELISA simultaneously with the samples. 
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5.5 HISTOLOGICAL ANALYSIS  
Lung sections (4 μm) were paraffin-embedded and stained with haematoxylin-eosin (Bio Optica, Milan, 
Italy) to measure bronchial wall thickness and tissue destruction, and Alcian blue–periodic acid–Schiff 
(AB-PAS) (Bio Optica, Milan, Italy) to evaluate goblet cell hyperplasia. Images of lung tissue sections 
were captured using a digital camera (AxioCam ICc1 R4; Zeiss, United States).  
5.5.1 BRONCHIAL WALL DIAMETER  
The thickness of the bronchial wall was measured by tracing around the basement membrane and the 
luminal surface of epithelial cells and calculating the mean distance between the lines using Axio Vision 
Rel. 4.8 software. A minimum of 10 bronchi per mouse measuring 150–350 μm luminal diameter were 
analysed by two separate double-blinded operators using Axio Vision Rel. 4.8 software (Zeiss, United 
States) which was calibrated with a reference micrometre slide. 
5.5.2 GOBLET CELL PERCENTAGE  
For goblet cell determination, using ImageJ software, AB-PAS-stained sections were evaluated and a 
percentage of the goblet cell area of each bronchus was assessed. A minimum of 10 bronchi per mouse 
were analysed by two separate double-blinded operators. 
5.5.3 EMPHYSEMA  
Pulmonary emphysema was quantified based on the degree of alveolar destruction, as determined by 
measuring the mean linear intercept (Lm) in micrometers. To measure the intercepts, a sheet with 10 
horizontal and 11 vertical lines was laid over the images. The Lm is obtained using the equation Lm = 
Ltot/Li, where Ltot is the total length of the lines in the microscopic field, and Li is the number of intercepts 
of alveolar structures with the lines of the reticulum
181
.  
5.5.4 IMMUNOHISTOCHEMICAL STAINING AND QUANTIFICATION  
Applied antibodies were subjected to in-house validation by the manufacturer for immunohistochemical 
analysis on paraffin-embedded material. The antibodies used in the study were anti-elastase, anti-TGFβ 
and anti-αSMA (ThermoScientific, Waltham, MA). Sections were deparaffinized with xylene and 
rehydrated with ethanol. Antigen retrieval was performed by placing the specimens in 0.25 mM EDTA 
solution (pH 8.0) at 95°C for 45 min. Slides were incubated in 3% H2O2 in methanol for 10 minutes to 
block endogenous peroxidases; primary antibodies were incubated overnight at 4°C and then with 
ImmPRESS reagents (VECTOR Laboratories, Burlingame, USA) for 30 minutes. Sections were 
incubated in DAB substrate kit for peroxidase (VECTOR Laboratories, Burlingame, USA) and 
counterstained. Using ImageJ software, immunostained sections were evaluated and a percentage of the 
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positive area of each bronchus was assessed. A minimum of 10 bronchi per mouse were analysed by two 
separate double-blinded operators. 
5.6 WESTERN BLOT  
Proteins were extracted from lung tissue using protein extraction buffer (150 mM sodium chloride; 1% 
Triton; 50 MM Tris pH 8.0; 1× protease inhibitor cocktail (ThermoScientific, Rockford, U.S.A.). Tissue 
was homogenized, maintained in constant agitation for 2 hours at 4°C and then centrifuged for 20 minutes 
at 13.000 g at 4°C. Protein concentrations were measured with QuantumMicro Protein assay (EuroClone, 
Pero, Italy). A total of 25 μg of protein lysates were subjected to SDS-PAGE on 12% acrylamide gel and 
transferred on to Amersham Hybond-ECL membrane (GE Healthcare, Orlando, FL). The blot was 
incubated with 5% non-fat dry milk at room temperature for 1 hour to block non-specific binding sites 
and then incubated for 2 hours at room temperature with specific antibodies against α-SMA, TGF-β and 
tubulin (Sigma-Aldrich, ST Louis, MO) as endogen control. The membrane was incubated in HRP-
conjugated secondary antibody for 1 hour at room temperature and detected with an ECL kit (LiteAblot 
Plus, EuroClone, Pero, Italy). 
5.7 AIRWAY RESPONSIVENESS  
Mice were sacrificed and bronchial tissues was rapidly dissected and cleaned from fat and connective 
tissue. Rings of 1-2mm length were cut and placed in organ baths mounted to isometric force transducers 
(Type 7006, Ugo Basile, Comerio, Italy) and connected to a Powerlab 800 (AD Instruments, Ugo Basile, 
Comerio, Italy). Rings were initially stretched until a resting tension of 0.5g was reached and allowed to 
equilibrate for at least 30 min. In each experiment bronchial rings were challenged with carbachol (10
-
6
mol/L) until the response was reproducible. Once a reproducible response was achieved bronchial 
reactivity was assessed performing a cumulative concentration-response curve to carbachol (1x10
-8
-3x10
-
5
mol/L). 
5.8 STATISTICAL ANALYSIS  
Data were analysed with Prism GraphPad statistical software (GraphPad Software, Inc., San Diego, CA, 
USA) using one-way analysis of variance (ANOVA), followed by post hoc comparison using 
Bonferroni’s t-test. We considered P values <0.05 to be significant. 
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6. RESULTS 
6.1 MURINE MODEL OF COPD 
PM10, LPS and smoke have a synergistic action, inducing an early and stronger activation of 
inflammation 
Evaluation of inflammatory cytokines in BAL collected from mice has shown that treatment with a 
combination of risk factors (PM-10, LPS and smoke) is able to trigger a strong and rapid inflammatory 
response in the first week of exposure. In the following weeks cytokine levels tended to reduce, 
particularly in the last week of exposure. This trend was not observed in groups exposed to single risk 
factors: indeed, they have shown a delayed inflammatory response (Fig. 1A,B,C). Moreover, gene 
expression of lungkine (CXCL15), which is involved in lung-specific neutrophil trafficking, was 
increased in all weeks of combined exposure, unlike what was observed in a single exposure that induced 
a significant increase of lungkine only in the last week of treatment with PM10 and LPS (Fig. 2). 
Interestingly, IL-10 levels were significantly reduced over control values in all groups from the third 
week of treatment. Therefore, it is evident that PM10, LPS and smoke have a synergistic action, 
anticipating the activation of inflammatory pathways and establishing a condition of chronic 
inflammation, highlighted by progressive lower levels of IL-10 (Fig. 1D). 
The degree of tissue destruction is progressively increased in all groups  
Gene expression of neutrophil elastase and MMP-9 is significantly increased in the sixth week of 
combined exposure (Fig. 3A); protein expression in bronchial tissue, evaluated by immunochemistry, is 
enhanced during all periods of combined exposure (Fig. 3B). Histological analysis has shown that both 
single and combined exposures were able to induce a progressive destruction of lung parenchyma, as 
particularly evidenced in the last week of combined treatment (Fig. 3C). 
Remodelling processes are progressively activated and lung function reduced    
Both single and combined exposures were able to progressively increase relative gene expression of key 
remodelling factors (TGF and SMA); levels are particularly high in the sixth week of combined 
treatment (Fig. 4A). These data were confirmed by the evaluation of bronchial tissue expression of these 
key proteins (Fig. 4B-C). Moreover, single and combined exposures were able to increase relative gene 
expression of kinases that activate S1P (SphK1-2) and receptor S1P3. The trend is similar to that 
observed with other remodelling factors (Fig. 5). 
Histological analysis has shown that all treatments are able to increase bronchial wall diameter and goblet 
cell hyperplasia, but this effect is particularly evident in the sixth week of combined exposure to risk 
factors (Fig. 6A-B). Moreover, we observed that B cells tend to organize into follicles only in groups 
exposed to a combination of factors, with more evidence in the last week of treatment (Fig. 6C). 
38 
 
Persistent lung injuries and consequent bronchial remodelling impair the physiological functions of the 
lung. This is confirmed by airway responsiveness measurements which has shown a progressive and 
significant decrease in bronchial reactivity in mice exposed to a combination of risk factors, particularly 
in those treated for 6 weeks (Fig. 7). 
Bronchial modifications are irreversible after treatment suspension    
After 6 weeks of exposure, discontinuation of treatment for another 4 weeks was unable to improve lung 
remodelling, as there were no significant changes in bronchial wall diameter, in tissue destruction and in 
goblet cell hyperplasia compared to mice treated and sacrificed at 1, 3 and 6 weeks of exposure (Fig. 8). 
 
6.2 THERAPY STUDY 
Cytokine release is reduced only with an early therapeutic treatment   
Anti-inflammatory and bronchodilator treatment significantly decreases levels of TNF, IL1- and GM-
CSF in a group early treated compared to untreated. No significant effects were observed in groups 
treated later, since levels of cytokines resulted similar between group untreated and those treated  (Fig. 
9A-B-C).  
Pharmacological treatment counteracts remodelling processes only if administered during early 
phase of lung injury  
Treatment with corticosteroids and bronchodilators, alone and/or in combination, was able to significantly 
decrease TGFand SMA mRNA levels in lungs, both in groups treated early than in those treated later 
(Fig. 10A). This trend was confirmed with immunochemistry which revealed a significant reduction in 
bronchial expression of proteins (Fig. 10B). These data demonstrate that pharmacological treatment had a 
positive effect on molecular pathway involved in remodeling processes, whatever the period of 
administration. 
Therapy with corticosteroid and bronchodilator drugs, particularly if combined, was able to significantly 
counteract lung tissue destruction, bronchial wall thickness and goblet cell hyperplasia when administered 
in the early stages. Indeed, bronchial alterations remained at control levels. Late treatment was able to 
contrast emphysema and goblet cell hyperplasia, but bronchial tissue resulted still significantly 
remodelled compared to controls (Fig. 11A-B-C). Similar trend was observed with lymphoid follicles 
positive for B cells, a marker of severe stage of COPD (Fig. 11D). 
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7. DISCUSSION 
7.1 COMBINED EXPOSURE TO CIGARETTE SMOKING, ENVIRONMENTAL 
POLLUTIONS AND LIPOPOLYSACCHARIDE REPRODUCES AN EXPERIMENTAL 
MURINE MODEL OF COPD 
In contrast to the large number of experimental studies of allergic airways inflammation, investigations 
into COPD are limited. The current challenge is to identify the role of different mediators and molecular 
mechanisms potentially involved in the pathophysiology of COPD, as no effective treatments able to 
reverse COPD progression have yet been discovered. Thus validation of animal models is necessary to 
understand pathological mechanisms and identify new therapeutic strategies. 
In 1965, Gross et al.
182
 demonstrated for the first time that the intratracheal instillation of papain could 
cause emphysema-like lesions in rats; moreover, a clinical study by Laurell and Erickson
64
 showed that 
patients deficient in α1-antitrypsin had an increased risk of emphysema. These data were the scientific 
basis for the hypothesis of protease–antiprotease imbalance in the pathogenesis of emphysema. In 
subsequent years additional animal models were developed, leading to a greater understanding of lung 
biology in pathological conditions similar to those of COPD. Models are generally based on the induction 
of emphysema-like lesions through the instillation of proteases, or on the triggering of a chronic 
inflammation via the inhalation of noxious agents (smoke or SO2)
161,177,180
, depending on the duration and 
doses required by the experimental protocol. An important approach is the use of knockout animals, such 
as PDGF-A-deficient mice, which develop emphysema.
172
 
In contrast to the complexity of COPD in humans, currently available animal models are limited because 
animals do not develop the disease spontaneously; moreover, experimental protocols reproduce a limited 
number of phenotypical characteristics, neglecting crucial aspects, such as exacerbations due to 
respiratory infection, that worsen airways inflammation (already present in COPD patients) and accelerate 
the decline of lung function. In addition, it is important to carefully evaluate morphological and molecular 
modifications to determine how far experimental models overlap with clinical observations in patients. 
The aim of this study was to validate an innovative COPD model based on combined exposure to the 
main risk factors: cigarette smoke, environmental pollution and bacterial exacerbations, using LPS that 
mimics injury by infections. Using molecular and morphological analysis, we compared single exposure 
to each factor as well as combined exposure, in order to highlight a possible synergistic effect between 
different treatments. In addition, a time course was performed by sacrificing animals at 1, 3 and 6 weeks 
of exposure, to monitor the progression of lung injury. The protocol lasted 6 weeks, as combined 
exposure for 9 weeks induces inflammation and remodelling processes that are no different from those in 
the group exposed for 6 weeks , thereby revealing a plateau of pathogenesis. 
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Assessment of proinflammatory cytokines in BAL showed that combined exposure to risk factors is able 
to induce a strong inflammatory response in the first week of treatment; in the following weeks levels of 
cytokines were reduced, but nevertheless remained significantly higher than in the control group, unlike 
what was found in the groups with a single exposure that showed a delayed inflammatory response. 
Interestingly, levels of IL-10 in BAL were reduced in all groups in the third and sixth weeks of exposure, 
with more evidence in groups exposed to a combination of factors; this is consistent with the low levels of 
IL-10 observed in patients with moderate/severe COPD and in smokers.
183
 Gene expression of CXCL15, a 
chemokine specifically expressed by lung bronchoepithelial cells and involved in lung-specific neutrophil 
trafficking
184
, was increased during all periods of combined exposure. Therefore, these data demonstrate 
that a combination of risk factors can induce an acute inflammatory response in the first week of 
treatment; in the following weeks a chronic inflammatory state is established, confirmed by lower levels 
of IL-10.  
A persistent inflammatory process leads to the release of several proteolytic enzymes, in particular by 
neutrophils and macrophages; an increase in lung parenchymal protease levels induces a progressive 
destruction of bronchial tissue, with consequent loss of alveolar attachments and emphysema. This 
condition activates repair processes through the release of several growth factors; over time, in pulmonary 
chronic diseases such as COPD, a continuous repair of tissue leads to a modification of the original 
architecture of the tissue, with consequent bronchial remodelling
185
. In this study we observed that gene 
expression levels of MMP-9 and neutrophil elastase were significantly increased only in groups with 
combined exposures from the third week onwards, with an evident peak in the sixth week of exposure. 
These data were confirmed by histological analysis, which showed a significant increase in emphysema-
like lesions, not only in groups exposed to a combination of factors, but also in groups exposed to smoke 
and to LPS. Further confirmation was derived by the detection of elastase by immunochemistry.  
We also analysed the key remodelling factors TGFβ and αSMA: several studies have confirmed that 
TGFβ, a profibrotic cytokine, is increased in the remodelled airways of patients with COPD186 and/or 
asthma.
187
 The fibrogenesis process depends on differentiation of fibroblasts into myofibroblasts, 
mediated by αSMA. An increase of αSMA release is directly induced by TGFβ, through Smads 
proteins.
106
 Moreover, Bossè et al.
188
 showed that TGFβ is responsible for the increased proliferation of 
bronchial smooth muscle cells, synergistically with FGF2. In our study, gene expression levels of these 
remodelling factors were significantly increased in the combined exposure groups in the third week of 
exposure, and even more increased in the sixth week. In a group treated with a single factor the trend was 
similar, albeit smaller. The detection of TGFβ and αSMA proteins using immunochemistry and Western 
blot analysis in bronchial tissue confirmed the results obtained with real-time PCR.  
We also analysed the expression of sphingosine-1-phosphate (S1P), as some studies have demonstrated 
its role in bronchial inflammation and remodelling; Kono et al.
189
 showed that activation of the 
SphK1/S1P pathway regulates the differentiation of fibroblasts into myofibroblasts, mediated by TGFβ 
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through the S1P3 receptor. The trend towards gene expression of kinases that activate S1P (SphK1-2) and 
receptor S1P3 is similar to that observed with other remodelling factors.  
Morphometric analysis showed that bronchial wall thickness is increased from the third week of 
exposure, and even more so in the sixth week, particularly in groups treated with a combination of risk 
factors. Similar data were observed with goblet cell hyperplasia, which is responsible for mucus 
hyperproduction and airflow obstruction in humans.
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Several clinical studies have demonstrated that the progression of COPD from mild to moderate/severe is 
characterized by the formation of lymphoid follicles positive for B cells, consistent with increased 
immune surveillance in the bronchial mucosa, as the close relationship between epithelium, APC cells 
and lymphoid follicles facilitates activation of the adaptive immune response.
51
 In this study we observed 
that B cells tend to organize into follicles in lung tissue in the sixth week of combined exposure, 
particularly around the bronchial walls. No significant evidence was observed in groups exposed to a 
single factor (data not shown). 
We evaluated pulmonary function through airway responsiveness measurements, which showed a 
progressive reduction in bronchial reactivity, with significant evidence in the last week of treatment; this 
is consistent with the hypothesis that continuous differentiation of fibroblasts into myofibroblasts impairs 
the physiological functions of the lung. 
Remodelling and loss of alveolar attachments are probably irreversible. This was an interesting result 
derived from the evaluation of bronchial structural changes 4 weeks after the cessation of treatment; we 
observed no significant variations from a group exposed for 6 weeks and immediately sacrificed, 
demonstrating that this protocol induces irreversible bronchial remodelling, even if the exposure to risk 
factors is suspended. 
Validation of new murine models must be based on the possibility of making comparisons between the 
morphological and molecular analyses in mice and clinical observations in patients. As described by 
Hogg
51
, the primary host defences against noxious stimuli are the innate and adaptive inflammatory 
immune responses. The innate defence system of the lung includes the mucociliary clearance system and 
the epithelial barrier, supported by the acute inflammatory response that follows tissue injury; chronic 
inflammation is then accompanied by irreversible alterations to lung tissue and small airway obstruction. 
Moreover, cigarette smoking alters the composition of the lung in such a way that fibrosis becomes self-
perpetuating, even after patients have stopped smoking.
191
 Indeed, the inflammatory changes in the 
airways caused by cigarette smoke exposure were only partially reversed after smoking cessation.  
The application of this new experimental protocol is able to trigger inflammatory processes which, in the 
later stages of exposure, induce destruction of the lung parenchyma and airways remodelling (bronchial 
wall thickening, goblet cell hyperplasia and B-cell follicles) that are irreversible after treatment cessation. 
This demonstrates that the pathogenesis observed in mice reflects the natural history of COPD.  
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Graphical representation of the progressive pathophysiological changes observed in this innovative murine 
model during all period of combined exposure to risk factors. 
Earlier stages of COPD are associated with more reversible changes, whereas later stages show more 
structural alterations and irreversibility. Thus a careful assessment of the structural phenotype of COPD 
patients is likely to lead to optimal categorization for trials, and earlier disease is more likely to respond to 
therapies. 
7.2 AN EARLY ANTINFLAMMATORY AND BRONCHODILATOR THERAPY 
COUNTERACTS LUNG INFLAMMATION AND REMODELLING PROCESSES 
Although COPD is a major global health problem with a rising incidence and morbidity, few 
pharmacotherapeutic advances have been made over the past decades. The disease causes approximately 
2.75 million deaths annually, and the number is projected to increase.
192
 COPD is characterized by 
progressively deteriorating lung function, accompanied by breathlessness (particularly after physical 
exertion), cough, sputum production, respiratory failure, and eventually death.
193,194
 The aim of COPD 
treatment should be to increase lung function, prevent disease progression, decrease symptoms and 
exacerbations, and improve quality of life;
195
 however, the approach to therapy has generally focused on 
symptomatic relief. With the exception of smoking-cessation programs for patients with early disease,
196
 
oxygen treatment for persistent hypoxemia,
197,198
 and lung-reduction surgery for selected patients with 
emphysema
150
 no treatment has been shown to reduce mortality. However, newer therapeutic strategies 
could improve quality of life and reduce serious morbidity, particularly exacerbations of disease and 
hospital admissions. 
The recently updated GOLD guidelines recognize that long-acting bronchodilator therapy is central to the 
symptomatic management of moderate COPD.
195
 LABAs, such as salmeterol, achieve this goal providing 
long-term sustained bronchodilation without tolerance;
133,199-200
 each dose improves airflow limitation for 
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more than 12 hours
201,202
, reduces breathlessness and exacerbation rate, and is associated with a clinically 
significant improvement in health status.
202
 The potential anti-inflammatory and cytoprotective properties 
of LABAs and the documented effect on exacerbation rate could have a significant impact on patient 
survival.  
Anti-inflammatory drugs, such as inhaled corticosteroids, have little or no effect on the rate of decline of 
lung function
203,204
, but may reduce the frequency of exacerbations
203,205
, especially when combined with 
an inhaled long-acting 2-agonist.
206
 Nevertheless, a combination therapy with corticosteroid and 2-
agonist doesn’t reduce mortality rate, as demonstrated by the TOwards a Revolution in COPD Health 
(TORCH) study. This randomized, double-blind trial compared salmeterol at a dose of 50 μg plus 
fluticasone propionate at a dose of 500 μg twice daily (combination regimen), administered with a single 
inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years. Outcomes 
for the comparison between the combination regimen and placebo were death from any cause, frequency 
of exacerbations, health status, and spirometric values. Although during the 3 years of the study 
combination regimen resulted in significantly fewer exacerbations, improved health status and lung 
function, as compared with placebo, it did not significantly reduce mortality from any cause.
147
  
The 4-year randomized, double-blind trial Understanding Potential Long-Term Impacts on Function with 
Tiotropium (UPLIFT) compared therapy with either tiotropium or placebo in patients with COPD. This 
study showed that tiotropium was associated with improvements in lung function, quality of life, and 
exacerbations, but did not significantly reduce the rate of decline in FEV1.
207
  
Current GOLD guidelines indicate an advantage in the use of long acting 2-agonists and/or 
anticholinergics combined with inhaled steroid in the moderate/severe stages, characterized by frequent 
exacerbations, even though these combination therapies administered in advanced stages of COPD seem 
to be unable to slow down the progression of the disease and reduce mortality. We hypothesize that a 
combined treatment could be useful to influence the progression of COPD only in the early stages of 
pathogenesis, when tissue damage is less relevant and bronchial structural changes are still reversible.  
To verify this statement, we set up an experimental therapeutic protocol using a previously described 
murine model of COPD, which requires a combined exposure to cigarette smoke, PM10 and bacterial 
LPS. The combined exposure is able to trigger inflammatory processes that, in the later stages, induce 
destruction of the lung parenchyma and airway remodelling such as bronchial wall thickening, goblet cell 
hyperplasia and B-cell follicles. These modifications were irreversible after exposure cessation, reflecting 
the natural history of COPD. Animals were treated at different times with a long acting 2-agonist 
(salmeterol), an anticholinergic (tiotropium) and a corticosteroid (fluticasone), either alone or in 
combination. One group was treated from the second week of exposure to harmful factors (early therapy), 
when remodelling is still insignificant; the other group began the therapy from the sixth week (late 
therapy), when remodelling processes are strongly activated. Drug treatments lasted 4 weeks in all 
groups.  
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Molecular and morphological evaluation was based on the comparison between the group with COPD-
like phenotype and not pharmacologically treated, and groups treated with different drug combinations, in 
order to assess the effects of early and late treatment on inflammatory and bronchial remodelling 
processes.  
In a first analysis, we evaluated BAL fluids cytokine levels through ELISA tests showing that early 
therapy was able to drastically reduce inflammation, while late therapy didn’t induce significant changes 
in the release of inflammatory cytokines, compared to untreated group. This result is consistent with those 
observed in preliminary studies on murine model where the inflammation reaches its peak in the early 
weeks of exposure to risk factors and tends to gradually decrease.  
We also analysed gene and tissue expression of key factors involved in tissue remodelling. Several 
studies confirmed that TGFβ, a profibrotic cytokine, is elevated in thickened airways and in BAL fluid of 
patients with asthma and/or COPD, suggesting a prominent role in bronchial modifications.
186,187
 Indeed, 
a hallmark of pulmonary remodelling is the differentiation of fibroblasts into myofibroblasts, typically 
mediated by αSMA.106 TGFβ contributes to lung fibrosis increasing fibroblast survival and inducing an 
increase in αSMA levels, by through the activation of Smad proteins. Moreover, Bosse and colleagues188 
showed that TGFβ is also responsible for increased proliferation and survival of bronchial smooth muscle 
cells, contributing to muscular hypertrophy and hyperplasia. We observed a significant reduction in gene 
and tissue expression of TGFβ and αSMA, both with early and late therapy, revealing a positive effect on 
molecular pathway, regardless of dosing time.  
Instead, histological analysis revealed a different trend for tissue modifications where only early 
treatment significantly counteracted the thickening of the bronchial wall and the emphysema, compared 
to untreated group. Assessment of goblet cell hyperplasia, responsible for mucus overproduction in the 
bronchial lumen, revealed that all groups had high percentages of mucus cells but only early therapy was 
able to significantly reduce them, particularly the triple therapy. Indeed, late pharmacological treatment 
reduces hyperplasia, although with a lesser effect. Several clinical studies have demonstrated that the 
progression of COPD from mild to moderate/severe is characterized by the formation of lymphoid 
follicles positive for B cells.
51
 Our data showed that bronchial tissue positivity to B lymphocytes was 
significantly reduced only with the early therapeutic treatment.  
In conclusion, these data confirmed that a late bronchodilator and anti-inflammatory therapy is not able to 
counteract tissue changes, despite effective action on gene and tissue expression of remodelling factors. 
Instead, an early pharmacological treatment reduces the peak of inflammation contributing to attenuate 
bronchial alterations that could be still reversible. 
Thus, the addition of an anti-inflammatory drug to bronchodilator therapy in the early stages, besides 
decrease symptoms, reduce exacerbations and improve quality of life, could be useful to increase lung 
function, decrease the extent of bronchial obstruction and effectively counteract the progression of the 
disease. 
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8. FIGURES  
FIGURE 1 
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Figure 1. ELISA tests on BAL to assess inflammatory cytokine levels. 
A. Single exposure to risk factor (PM10, LPS, smoke) is able to increase TNFα levels from the third week 
of treatment, with particular evidence in the sixth one in groups exposed to LPS and smoke († p<0,001 vs 
PM10 1wk; ‡ p<0,001 vs LPS 1wk; § p<0,001 vs smoke 1 wk). Combined exposure enhances TNFα 
levels in the first week with a progressive and significant reduction in the following weeks (II p<0,001 vs 
P+L+S 1 wk). 
B. IL-1β levels are significantly enhanced in the third and sixth week of single exposure († p<0,001 vs 
PM10 1wk; ‡ p<0,001 vs LPS 1wk; § p<0,001 vs smoke 1 wk). Treatment with a combination of risk 
factors significantly increases cytokine levels in the first and third week of treatment; in the sixth weeks 
levels return to basal values (II p<0,001 vs P+L+S 1 wks). 
C. GM-CSF dosage has shown significant high levels in the first week of single treatment with PM10 and 
LPS († p<0,001 vs PM10 1 wk; ‡ p<0,001 vs LPS 1 wk). Combined exposure enhances levels in the first 
and third week of treatment (II p<0,001 vs P+L+S 6 wks). 
D. In all groups of treatment levels of IL-10 are significantly reduced during the third and sixth week of 
exposure († p<0,001 vs PM10 1 wk; ‡ p<0,001 vs LPS 1 wk; § p<0,001 vs smoke 1 wk; II p<0,001 vs 
P+L+S 1 wk). 
* p<0,001 vs CTRL. Data represent the mean ± SD. 
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FIGURE 2 
 
 
 
 
Figure 2. CXCL15 (murine homologue of human IL-8) mRNA expression in lungs determined by 
real-time PCR analysis. 
* p<0,001 vs CTRL. Data represent the mean ± SD. 
49 
 
FIGURE 3 
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Figure 3. Evaluation of gene and tissue expression of proteolytic enzymes and assessment of the 
degree of lung destruction.  
A. Real time PCR showed a significant increase of elastase relative gene expression in the sixth week of 
combined exposure (II p<0,001 vs P+L+S 1-3 wks). Relative gene expression of MMP9 increased in the 
sixth week of combined exposure ( II p<0,001 vs P+L+S 1-3 wks).  
B. Assessment of positive bronchial area to elastase immunoreaction has shown that protein expression 
is significantly increase in the sixth week of exposure to LPS ( ‡ p<0,001 vs LPS 1-3 wks), in all groups 
exposed to smoke (* p<0,001 vs CTRL) and to a combination of risk factors, with particolar evidence in 
the sixth week (II p<0,001 vs P+L+S 1-3 wks). 
C. Representatives images of haematoxylin-stained lung section (20X) in control mice (I), in mice 
exposed to a combination of smoke, PM10 and LPS for 1 week (II), 3 weeks (III) and 6 weeks (IV).  
Evaluation of Mean Linear Intercept on lung tissue section has shown significant variations in group 
exposed for 6 weeks to LPS, to smoke and to a combination of three factors (II p<0,001 vs P+L+S 1-3 
wks). 
* p<0,001 vs CTRL. Data represent the mean ± SD.  
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FIGURE 4 
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Figure 4. Gene and tissue expression of remodelling key factors, TGFβ and SMA. 
A. Relative gene expression of TGFβ and SMA, analysed through real time PCR, is significantly 
increased in groups exposed to LPS, smoke and to a combination of toxic agents (‡ p<0,001 vs LPS 1wk; 
§ p<0,001 vs smoke 1wk; II p<0,001 vs P+L+S 1 wk). 
B. Representatives images of TGFβ-positive bronchial area (20X) in lung of control mice (I), mice 
exposed to a combination of smoke, PM10 and LPS for 1 week (II), 3 weeks (III) and 6 weeks (IV). 
Analysis of positive bronchial area to TGFβ immunoreaction has shown a significant increase in tissue 
expression in groups exposed to LPS for 6 weeks (‡ p<0,001 vs LPS 1 wk and 3 wks), in groups treated 
with smoke for 3 and 6 weeks (§ p<0,001 vs smoke 1 wk) and in all those exposed to a combination of 
risk factors (ll p<0,001 vs P+L+S 1 wk). 
Tissue expression of SMA resulted significantly enhanced in groups exposed only to smoke (§ p<0,001 
vs smoke 1 wk) and in groups treated with a combination of agents, particularly in the sixth week of 
exposure (II p<0,001 vs P+L+S 1 wk). 
C. Western blot analysis has shown a significant increase in SMA and TGFβ tissue expression in 
group exposed for 6 weeks to a combination of risk factors (ll p<0,01 vs P+L+S 1-3 wks). 
* p<0,01 vs CTRL. Data represent the mean ± SD. 
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FIGURE 5 
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Figure 5. Gene expression of kinases that activate S1P (SphK1-2) and receptor S1P3. 
Relative gene expressions of SphK1, SphK2 and S1P3 receptor, analysed through real time PCR, are 
significantly increased in groups exposed to LPS, smoke and to a combination of toxic agents (‡ p<0,001 
vs LPS 1wk; § p<0,001 vs smoke 1wk; ‖ p<0,001 vs P+L+S 1wk; II p<0,001 vs P+L+S 1 wk). 
* p<0,01 vs CTRL. Data represent the mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
FIGURE 6 
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Figure 6. Evaluation of remodelling processes: bronchial wall thickeness, goblet cells 
hyperplasia and B cell-positive lymphoid follicles. 
A. Representatives images of haematoxylin-stained bronchial sections (20X) in control mice (I), in mice 
exposed to a combination of smoke, PM10 and LPS for 1 week (II), 3 weeks (III) and 6 weeks (IV). 
Measurement of bronchial wall diameter (μm) has shown a significant thickening in all groups of 
exposure (* p<0,001 vs CTRL). In particular, combined treatment induces a progressive increase in wall 
diameters, with a peak in the sixth week of exposure (II p<0,001 vs P+L+S 1 wk and 3 wks). 
B. Representatives images of  P.A.S.-stained lung sections (20X) in control mice (I), in mice exposed to 
a combination of smoke, PM10 and LPS for 1 week (II), 3 weeks (III) and 6 weeks (IV). 
Percentage of P.A.S. positive area resulted increased in all groups treated, particularly in those exposed to 
a combination of risk factors for 6 weeks (II p<0,001 vs P+L+S 1-3 wks). 
C. Representatives images of B cell-positive bronchial area (anti CD45, 20X) in lung of mice untreated 
and those exposed to a combination of smoke, PM10 and LPS for 1 week, 3 weeks and 6 weeks. B cells 
localized around bronchial wall from the first week of combined exposure, and tend to organize into 
follicles in the third and sixth week of treatment. No significant positive immunoreaction was observed in 
groups exposed to a single toxic agent (data not shown). 
* p<0,01 vs CTRL. Data represent the mean ± SD. 
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FIGURE 7 
 
 
Figure 7. Evaluation of lung function.  
Airway responsiveness measurements revealed a progressive reduction of lung contractility, significant at 
the sixth week of exposure to noxious agents. 
* p<0,01 vs CTRL. Data represent the mean ± SD. 
 
 
 
 
 
64 
 
FIGURE 8  
 
 
 
 
Figure 8. Evaluation of histological changes in a group treated for 6 weeks followed by a 
suspension of exposure for 4 weeks, compared to groups treated for 1, 3 and 6 weeks.  
Measurements of bronchial wall diameter (μm), Mean Linear Intercept and percentage of P.A.S. positive 
area have shown no significant variations after a suspension of treatment for 4 weeks, compared to groups 
treated and sacrificed at first, third and sixth week of exposure. 
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FIGURE 9 
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Figure 9. ELISA tests on BAL to measure inflammatory cytokine levels.  
A. TNFlevels, were significantly decreased in groups early treated with a combination 
fluticasone+salmeterol, fluticasone+tiotropium and fluticasone+salmeterol+tiotropium, compared to the 
group untreated  (‡ p<0,001 vs P+L+S 5wks). No significant variations were observed in grouped treated 
later. No significant variations were observed in grouped treated later. 
B. IL1 dosage showed that cytokine levels were reduced in all groups early treated (‡ p<0,001 vs 
P+L+S 5wks). No significant variations were observed in grouped treated later. 
C. Levels of GM-CSF were significantly decreased in groups early treated with a combination 
fluticasone+salmeterol, fluticasone+tiotropium and fluticasone+salmeterol+tiotropium, compared to the 
group untreated  (‡ p<0,001 vs P+L+S 5wks). No significant variations were observed in grouped treated 
later. 
* p<0,01 vs CTRL. Data represent the mean ± SD. 
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FIGURE 10 
A.  
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Figure 10. Gene and tissue expression of TGF and SMA. 
A. Relative gene expression of TGF and SMA, evaluated through real time PCR, was significantly 
reduced by early and late treatment (‡ p<0,001 vs P+L+S 5wks; § p<0,001 P+L+S 9wks). 
B. Representatives images of TGFβ-positive bronchial area (20X) in lung of mice exposed to risk 
factors for 5 weeks and not treated, mice exposed to risk factors for 5 weeks and treated with 
fluticasone+salmeterol+tiotropium, mice exposed to risk factors for 9 weeks and not treated, mice 
exposed to risk factors for 9 weeks and treated with fluticasone+salmeterol+tiotropium. 
Analysis of positive bronchial area to TGFβ and SMA immunoreaction has shown a significant 
reduction in tissue expression in all groups early treated (‡ p<0,001 vs P+L+S 5wks) and in groups 
treated later with fluticasone, fluticasone+salmeterol, fluticasone+tiotropium and 
fluticasone+salmeterol+tiotropium (§ p<0,001 vs P+L+S 9wks). 
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FIGURE 11 
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Figure 11. Morphometric analysis of lung sections to evaluate remodelling processes: tissue 
destruction, bronchial wall thickness, goblet cells hyperplasia and B cell -positive lymphoid 
follicles. 
A. Representatives images of haematoxylin-stained lung section (20X) in control mice (I), in mice 
exposed to a combination of smoke, PM10 and LPS for 1 week (II), 3 weeks (III) and 6 weeks (IV). 
Evaluation of Mean Linear Intercept on lung tissue section has shown that early treatment with 
fluticasone+salmeterol, fluticasone+tiotropium and fluticasone+salmeterol+tiotropium and late therapy 
with  fluticasone+tiotropium and fluticasone+salmeterol+tiotropium were able to contrast processes that 
induce emphysema (‡ p<0,001 vs P+L+S 5wks; § p<0,05 P+L+S 9wks). 
B. Representatives images of haematoxylin-eosin stained lung section (20X) of mice exposed to risk 
factors for 5 weeks and not treated, mice exposed to risk factors for 5 weeks and treated with 
fluticasone+salmeterol+tiotropium, mice exposed to risk factors for 9 weeks and mice exposed to risk 
factors for 9 weeks and treated with fluticasone+salmeterol+tiotropium.  
Measurement of bronchial wall diameters showed that only groups early treated with 
fluticasone+salmeterol, fluticasone+tiotropium and fluticasone+salmeterol+tiotropium had a diameter 
significantly reduced compared to untreated (‡ p<0,001 vs P+L+S 5wks). 
C. Representatives images of P.A.S.-stained lung section (20X) of mice exposed to risk factors for 5 
weeks and not treated, mice exposed to risk factors for 5 weeks and treated with 
fluticasone+salmeterol+tiotropium, mice exposed to risk factors for 9 weeks and mice exposed to risk 
factors for 9 weeks and treated with fluticasone+salmeterol+tiotropium. 
Percentage of P.A.S. positive area resulted reduced in groups early treated with fluticasone, tiotropium, 
fluticasone+salmeterol, fluticasone+tiotropium († p<0,05 vs P+L+S 5wks) and  particularly 
fluticasone+salmeterol+tiotropium (‡ p<0,001 vs P+L+S 5wks). Goblet cells were decreased in groups 
treated later with tiotropium, fluticasone+salmeterol, fluticasone+tiotropium and 
fluticasone+salmeterol+tiotropium (§ p<0,05 vs P+L+S 9wks).  
D. Representatives images of B cell-positive bronchial area (anti CD45, 20X) in lung of mice exposed 
to risk factors for 5 weeks and not treated, mice exposed to risk factors for 5 weeks and treated with 
fluticasone+salmeterol+tiotropium, mice exposed to risk factors for 9 weeks and mice exposed to risk 
factors for 9 weeks and treated with fluticasone+salmeterol+tiotropium. 
Early therapy counteracts the formation of B cells positive lymphoid follicles, compared to untreated. No 
significant differences were observed between groups treated later and group untreated. 
* p<0,01 vs CTRL. Data represent the mean ± SD. 
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